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Elizabeth Marie Runge 
THE ROLE OF INTERLEUKIN-10 IN CD4+ T CELL-MEDIATED 
NEUROPROTECTION AFTER FACIAL NERVE INJURY 
The adaptive arm of the immune system is necessary for facial motoneuron 
(FMN) survival after facial nerve axotomy (FNA). CD4+ T cells mediate FMN survival 
after FNA in an interleukin-10 (IL-10) dependent manner, but are not themselves the 
cellular source of neuroprotective IL-10. The aims of this study are to elucidate the 
neuroprotective capacity of cell-specific IL-10 expression, and to investigate the manner 
in which CD4+ T cells participate in IL-10 signaling after FNA.  
Immunohistochemistry revealed that FMN themselves were constitutive 
producers of IL-10, and astrocytes were induced to make IL-10 after FNA. Il10 mRNA 
co-localized with microglia before and after axotomy, but microglial production of IL-10 
protein was not detected. To determine whether any single source of IL-10 is critical for 
FMN survival, Cre/Lox mouse strains were utilized to selectively knock out IL-10 in 
neurons, astrocytes, and microglia. In agreement with the localization data reflecting 
concerted IL-10 production by multiple cell types, no single cellular source of IL-10 was 
necessary for FMN survival.  
Gene expression analysis of wild-type, immunodeficient, and immune cell-
reconstituted animals was performed to determine the role of the immune system in 
modulating the central IL-10 signaling cascade. This revealed that CD4+ T cells were 
necessary for full upregulation of central IL-10 receptor (IL-10R) expression after FNA, 
regardless of their own IL-10R beta (IL-10RB) expression or IL-10R signaling capability. 
Surprisingly, the ability of CD4+ T cells to respond to IL-10 was critical for their ability 
 
ix 
to mediate neuroprotection. Adoptive transfer of IL-10RB-deficient T cells resulted in 
increased central expression of genes associated with microglial activation, antigen 
presentation, T cell co-stimulation, and complement deposition in response to injury. 
These data suggest that IL-10RB functions on the T cell to prevent non-neuroprotective 
immune activation after axotomy.  
The conclusions drawn from this study support a revised hypothesis for the 
mechanisms of IL-10-mediated neuroprotection, in which IL-10 serves both trophic and 
immune-modulating roles after axotomy. This research has implications for the 
development of immune-modifying therapies for peripheral nerve injury and motoneuron 
diseases.  
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CHAPTER 1: INTRODUCTION 
 
 Damage to peripheral nerves results in significant disability due to impairment of 
motor, sensory, and autonomic functions. The National Institute of Neurological 
Disorders and Stroke estimates that 20 million Americans suffer from some form of 
peripheral neuropathy (NINDS, 2018). Although nerve damage due to direct trauma is 
rarer than diabetes- or chemotherapy-induced neuropathy, it is estimated that between 
two and five percent of patients admitted to Level I trauma centers have some form of 
peripheral nerve injury (PNI) (Noble et al., 1998). Among military personnel, the 
incidence is much higher. Approximately 15% of medically retired Army service 
members have sustained some form of PNI (Rivera et al., 2014). Healthcare costs for the 
treatment of PNI can range from a median of $18,000/case for single nerve injuries to 
over $34,000/case for complex brachial plexus injuries (Lad et al., 2010). In spite of the 
substantial costs of treating these injuries, clinical outcomes are poor. Only 10% of nerve 
injuries that require surgical repair have outcomes comparable to their pre-injury 
functional capacity (Portincasa et al., 2007). Improved therapies that promote better 
outcomes after nerve injury are greatly needed. Understanding the mechanisms of 
recovery after PNI will likely also aid in the discovery of therapies for other axonopathies 
such as amyotrophic lateral sclerosis (ALS). Similar to PNI, a precipitating insult on the 
distal portion of the motor unit is theorized to be a significant contributing factor in the 
pathogenesis of ALS (Fischer et al., 2004; Mariotti & Bentivoglio, 2000; Morgan & 
Orrell, 2016). 
 There are three basic requirements for functional recovery after PNI: 1) central 
neuron survival, 2) axon regeneration, and 3) reconnection to target. Because 
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motoneurons are post-mitotic and cannot be replaced after injury, promoting neuron 
survival is paramount for successful recovery. Neuro-immune interactions promote 
neuron survival after injury. After facial nerve axotomy (FNA), immunodeficient mice 
that lack the adaptive arm of the immune system have decreased facial motoneuron 
(FMN) survival in the facial motor nucleus (FMNuc) compared to wild-type (WT) mice 
with functioning immune systems (Serpe et al., 1999; Serpe et al., 2000). This 
neuroprotective effect has been determined to be specific to CD4+ T cells (Serpe et al., 
2003). CD4+ T cells must encounter major histocompatibility complex class II (MHCII) 
on antigen presenting cells (APCs) in the periphery to obtain their neuroprotective ability 
(Byram et al., 2004). Most major subsets of CD4+ T cells expand in the draining deep 
cervical lymph nodes after FNA (Xin et al., 2008). Only the T helper cell 2 (Th2) subset 
has been identified as critical for motoneuron survival after FNA, although both the Th1 
and Th2 subsets may be important for axon regeneration (Beahrs et al., 2010; Deboy et 
al., 2006b). Having encountered MHCII and multiplied peripherally, T cells are next 
attracted to the FMNuc by centrally-derived chemokines (Wainwright et al., 2009a; 
Wainwright et al., 2009b; Wainwright et al., 2009c), where they must again encounter 
MHCII on a central APC in order to confer neuroprotection (Byram et al., 2004). 
 The precise manner in which CD4+ T cells mediate motoneuron survival in the 
FMNuc after axotomy is unknown. The secretion of neurotrophic factors (NTFs) is one 
potential mechanism, although studies of the FMNuc have failed to find a T cell-specific 
NTF that is necessary for FMN survival (Serpe et al., 2005; Xin et al., 2012). 
Furthermore, axotomy triggers FMN to upregulate expression of molecules that are 
important for axonal regeneration, regardless of the presence of CD4+ T cells. Recent 
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studies have indicated that CD4+ T cells may rather exert their neuroprotective influence 
by regulating the glial response to axotomy (Setter et al., 2018b). 
 The anti-inflammatory cytokine interleukin-10 (IL-10) may be an important 
mediator of the neuroprotective capability of CD4+ T cells. IL-10 was first discovered as 
a Th2-produced cytokine capable of suppressing pro-inflammatory cytokine production 
by Th1 cells (Fiorentino et al., 1989). Its sources and actions are now understood to be 
much more diverse (Moore et al., 2001). CD4+ T cells cannot mediate FMN survival 
when IL-10 is absent; however, they themselves are not the requisite source of IL-10. It is 
likely that a central cell type in the FMNuc mediates FMN survival via IL-10 production 
(Xin et al., 2011). Although IL-10 is required for CD4+ T cells to confer neuroprotection, 
the central cellular source of IL-10 as well as the details of T cell involvement in the IL-
10 signaling cascade in the axotomized FMNuc have not been previously identified. This 
information is necessary to understand the process of endogenous immune-mediated 
neuroprotection and thereby identify potential mechanisms that can be exploited for the 
treatment of nerve injury and disease. The central hypothesis for this study is that CD4+ 
T cells are critical for potentiating microglial-derived IL-10 signaling and facilitating its 
neuroprotective capacity in the FMNuc.  
This hypothesis was tested in the following aims: 
Aim 1: Determine the central cellular sources of IL-10 in the facial motor 
nucleus and the respective contributions of these sources to motoneuron survival 
after axotomy. The hypothesis for this aim is that microglia are the obligate source of 
neuroprotective IL-10 after axotomy. After ruling out a peripheral immune contribution 
of neuroprotective IL-10, the first part of this aim was tested using two methods of 
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immunohistochemical (IHC) identification of IL-10-producing cells, as well as 
fluorescent in situ hybridization (FISH) for Il10 mRNA in the FMNuc. The results reveal 
that FMN produce IL-10 constitutively, whereas IL-10 expression is induced by axotomy 
in astrocytes. Microglia co-localize with Il10 mRNA, but protein translation is not 
apparent. For the second part of this aim, IL-10 was selectively knocked out in neurons, 
astrocytes, and microglia using Cre/Lox technology. Concordant with the localization 
data, no single cellular source of IL-10 is necessary for FMN survival. It is concluded 
that the multiple central sources of IL-10 have redundant roles for FMN survival after 
axotomy. 
Aim 2: Characterize adaptive immune cell participation in neuroprotective 
IL-10 receptor signaling after facial nerve axotomy. The hypothesis for this aim is that 
CD4+ T cells are necessary for central IL-10 receptor expression and directly respond to 
IL-10 themselves to confer neuroprotection. IHC labeling was utilized to determine that 
CD4+ T cells are capable of interacting directly with central cells in the FMNuc and thus 
may regulate changes in central gene expression via cell-cell interactions. Quantitative 
polymerase chain reaction (qPCR) analysis for IL-10 receptor (IL-10R) gene expression 
was performed in the FMNuc of WT, immunodeficient, and CD4+ T cell-reconstituted 
animals. The results indicate that CD4+ T cells are necessary for full induction of IL-10R 
gene expression after axotomy, although this induction does not appear to depend upon 
IL-10 signaling by the T cells themselves. However, IL-10 signaling by CD4+ T cells is 
necessary for their ability confer neuroprotection. CD4+ T cells deficient in IL-10R 
expression promote a gene expression signature in the FMNuc suggestive of enhanced 
microglial activation, antigen presentation, T cell co-stimulation, and complement 
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deposition, indicating that T cells unresponsive to IL-10 may promote a state of immune 
activation detrimental to FMN survival. A future direction will be to determine whether 
this failure to mediate FMN survival is due simply to loss of normal Th2-mediated 
neuroprotective mechanisms, or to counteraction of these mechanisms by an opposing T 
cell process that is actively harmful to FMN survival. 
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CHAPTER 2: LITERATURE REVIEW 
 
2.1. Peripheral nerve injury 
2.1.1. Anatomic organization and basic principles 
 In simplified terms, the role of the nervous system is to receive information from 
the internal or external physical environment, process and integrate these signals, and 
convey a response of the body to stimuli. Neurons and glia are two main cell types 
constituting the nervous system. Neurons are highly specialized cells that are optimized 
for the transmission of signals. Glial cells, which are the more abundant cell type in the 
nervous system, have numerous and complex roles that fundamentally maintain the 
environment necessary for neurons to perform their functions. Anatomically, the nervous 
system can be divided into central and peripheral compartments. The central nervous 
system (CNS) consists of the brain and spinal cord, and the peripheral nervous system 
(PNS) consists of ganglia and nerves. The PNS can be further subdivided on a functional 
basis into sensory, motor, autonomic, and enteric cell populations.  
 Voluntary movement requires coordinated activity by both upper and lower 
motoneurons (UMNs and LMNs). UMN cell bodies reside in the cortex of the brain and 
project axons that travel in white matter bundles called tracts. These axons synapse on 
LMNs that reside in brainstem nuclei and spinal cord columns. LMNs project axons that 
exit the CNS and form peripheral nerves that terminate at specialized synapses called 
neuromuscular junctions (NMJ). At the NMJ, motoneuron impulses that are sent to target 
muscle fibers trigger a cascade of events that ultimately results in muscle contraction.  
Trauma to peripheral nerves results in interruption of these signals and failure of 
voluntary movement. Types of nerve injuries are categorized according to their severity. 
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Neurapraxia is the mildest form of nerve injury in which the myelin sheath is damaged 
but axons are left intact, resulting in a temporary conduction block followed by complete 
and rapid recovery. This type of injury typically occurs due to nerve compression. 
Axonotmesis, which occurs after crush or contusion injury, is more severe than 
neurapraxia because it constitutes axotomy (severing of the axon) followed by 
subsequent degeneration. However, the connective tissue sheaths surrounding the injured 
axons, fascicles, and nerves (termed the endoneurium, perineurium, and epineurium, 
respectively) remain intact to guide subsequent regeneration. With this neural sheath 
intact, regeneration can occur at a rate of 1–5 mm/day, depending on the size of the 
nerve. Neurotmesis is the most severe form of injury characterized by complete 
transection of the axon and nerve sheath (Seddon, 1942; Seddon et al., 1943; Sunderland, 
1951). This form of injury is most likely to result in death of the central cell body, 
although the amount of neuronal death that occurs after axotomy is variable (Moran & 
Graeber, 2004). 
Because motoneurons are terminally differentiated, they cannot multiply to 
replace neurons that have died after axotomy. Promoting central neuron survival is 
critical for subsequent axon regeneration, reconnection to target, and functional recovery. 
The development of therapies for nerve injury will depend on elucidation of the 
mechanisms that determine whether a neuron survives or dies after axotomy. A 





2.1.2. The facial nerve axotomy model 
2.1.2.1. Anatomy and topographic organization 
 The facial nerve receives its motor contribution from neurons in the FMNuc, 
which is located in the dorsal pons in humans and the ventral pons in rodents. Axons 
from the FMNuc travel dorsally and loop around the abducens nucleus, forming a 
structure called the genu, prior to exiting the ventral pons. This unusual course is due to 
migration of facial motoneurons around the abducens nucleus during embryogenesis 
(Chandrasekhar, 2004). The intracranial portion of the nerve is joined by the nevus 
intermedius, which is composed of parasympathetic fibers from the superior salivary 
nucleus in the pons and both general and special sensory fibers from the geniculate 
ganglion en route to brainstem sensory nuclei. As a mixed nerve, the facial nerve enters 
the internal acoustic meatus located in the petrous portion of the temporal bone and 
travels through the facial canal of the skull. In the facial canal, most non-motor fibers 
diverge to join the greater petrosal nerve and the chorda tympani. A short motor branch 
also emerges to innervate the stapedius muscle of the inner ear. Immediately after the 
facial nerve exits the stylomastoid foramen, the posterior auricular nerve and branches to 
the stylohyoid and digastric muscles diverge from the main nerve trunk. Some reports 
indicate that the posterior auricular nerve also contains a sensory component (Semba & 
Egger, 1986). The remaining main trunk of the facial nerve consists only of motor fibers. 
The facial nerve then enters the parotid gland and splits into its five main terminal 
branches: temporal, zygomatic, buccal, marginal mandibular, and cervical. These 
branches innervate the muscles of facial expression and the platysma. 
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 Because none of the muscles that the facial nerve innervates cross a joint, the 
FMNuc consists of a pure α-motoneuron population without any γ-motoneurons 
necessary for innervation of muscle spindles. The number of FMN in the FMNuc vary 
according to species, and estimates range from 2000–3000 in mouse (Ashwell, 1982) to 
3000–5000 in rat (Semba & Egger, 1986; Watson et al., 1982). The FMNuc is divided 
into three main columns (Watson et al., 1982) and six subnuclei (Ashwell, 1982). These 
divisions follow a “mirror-image” somatotopic organization. The dorsal and ventral 
regions of the FMNuc innervate the upper (frontalis and orbicularis oculi) and lower 
(mentalis) facial muscles, respectively. Medial-lateral organization of the FMNuc is 
reversed: the lateral subnuclei consists of neurons that project somewhat to the midline 
(vibrissae and nasolabial muscles), the intermediate subnuclei project to the buccal 
muscles/facial platysma, and the medial to the temporal and auricular muscles (Ashwell, 
1982; Komiyama et al., 1984; Semba & Egger, 1986; Watson et al., 1982). 
 
2.1.2.2. The facial nerve axotomy as a model of target disconnection-induced 
motoneuron death 
 FNA is a useful model of motoneuron injury for a number of reasons. If lesioned 
close to its emergence from the stylomastoid foramen, only motor fibers will be 
damaged. The mostly homogenous population of α-motoneurons housed in the FMNuc 
allow for their study without dilution by other uninjured neuron populations. There are 
also no interneurons or cross-talk between contralateral FMNuc; thus, the uninjured side 
may be used as a paired internal control (Isokawa-Akesson & Komisaruk, 1987). FNA 
does not cause any physical disruptions affecting blood-brain barrier permeability 
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(Raivich et al., 1998), and infiltration of the FMNuc by peripheral macrophages is not 
observed after axotomy (Graeber et al., 1988c). Finally, FNA is a relatively mild injury 
that does not result in loss of vital functions of the animal (Jones et al., 2015). 
 The extent of FMN death that occurs after FNA is dependent on a number of 
variables. In general, FMN death as well as time to regeneration is greater after proximal 
compared to distal lesions (Dai et al., 2000; Mattsson et al., 1999; Sharma et al., 2009). 
Avulsion injury causes the most severe phenotype, although this is probably due to 
disturbance of the blood-brain barrier, which is unique to this form of axotomy (Soreide, 
1981a). There is also significant variability in the amount of FMN death between species. 
Hamsters have virtually no FMN death after axotomy at the stylomastoid foramen 
(Huppenbauer et al., 2005), whereas mice have approximately 15% FMN death at four 
weeks post lesion and 50% death at ten weeks post lesion (Serpe et al., 2000; Setter et al., 
2018a). The age at which the axotomy is performed is also a significant factor to FMN 
death. Embryonic and neonatal animals have significantly greater rates of FMN death 
after axotomy than adult animals, possibly due to the reliance of motoneurons on target-
derived growth factors during the developmental period (Huppenbauer et al., 2005; 
Lavelle & Lavelle, 1959; Soreide, 1981b). Different subnuclei within the FMNuc also 
exhibit different amounts of FMN death. Although the overall average amount of FMN 
death at one month post axotomy in mice is approximately 15%, the ventrolateral 
subnucleus has the greatest amount of cell death at 30%, whereas the ventromedial 
subnucleus has the least amount of death at 3% (Canh et al., 2006). This discrepancy may 
be due to the greater distance of the lateral nuclei from NTFs provided by penetrating 
blood vessels from the basilar artery, which is located at the ventral midline of the 
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brainstem, or perhaps due to intrinsic differences in motoneurons that innervate different 
muscle groups.  
 
2.1.3. Central responses to axotomy 
 The responses of neurons, astrocytes, and microglia to axotomy constitute a CNS 
reaction historically referred to as the “axon reaction” (Lieberman, 1971) or “nerve cell 
body response to injury” (Grafstein, 1975). The individual elements that constitute this 
reaction are discussed below. 
 
2.1.3.1. Motoneuron response 
 In 1892, renowned neuropathologist Franz Nissl described using aniline dyes to 
stain granular basophilic structures in FMN cell bodies (Danilevicius, 1968; Nissl, 1892). 
These structures came to be known as “Nissl bodies” or “Nissl substance”. Nissl 
substance was later determined to be the ribosome-studded rough endoplasmic reticulum 
(RER), which stains with basic dyes due to an abundance of ribonucleic acid (RNA) 
(Palay & Palade, 1955). In axotomized FMN, one of the earliest changes observable by 
light microscopy is dispersion of the large Nissl bodies into finer particles 
(Cammermeyer, 1955; Cragg, 1970). This dispersion of the Nissl bodies causes paling of 
the perinuclear cytoplasm, known as chromatolysis, which can be observed after axotomy 
in both rodents and humans (Graeber et al., 1993; Lavelle & Lavelle, 1959). Conversely, 
an overall increase in general cytoplasmic basophilia has also been reported after 
axotomy (Cammermeyer, 1955; Torvik & Skjorten, 1971a). Electron microscopy 
revealed that these phenomena are due to segmentation and dispersion of RER cisterns 
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and a complementary shift in the predominant location of ribosome clusters from the 
RER to the cytoplasm (Torvik & Skjorten, 1971a). These events are accompanied by 
eccentric displacement and swelling of the motoneuron nucleus and nucleolus, indicating 
an overall increase in RNA transcription, manufacture of ribosomes, and downstream 
protein synthesis (Cammermeyer, 1955; Cragg, 1970; Grafstein, 1975; Lieberman, 1971). 
These changes reflect a shift in the prioritization of neuronal resources away from 
neurotransmission (RER membrane-associated translation) toward anabolic regeneration 
(cytoplasmic translation), and in some ways recapitulates the pattern of translation that 
occurs during the developmental period (Griffith & La Velle, 1971). 
 The precise trigger for the axon reaction is unknown. Loss of axoplasm volume, 
depolarization of the neuron, and failure of action potentials have been proposed as 
causative factors (Cragg, 1970; Grafstein, 1975). However, these do not explain the 
discrepancy in onset of nucleolar swelling after distal versus proximal lesions, a 
difference attributable to some retrograde signal that travels at a rate of approximately 4–
5 mm/day. If the retrograde transport of trophic factors in the proximal portion of the 
severed axon continues after axotomy, the eventual cessation of these trophic factors 
reaching the cell body may constitute this signal (Cragg, 1970). It is most likely a 
combination of signals that prompts the motoneuron to switch from a neurotransmission-
focused to a regeneration-focused metabolic state. 
 Differential production of specific molecules in the pre- and post-axotomy state 
demonstrates this shift of focus. After axotomy, smooth endoplasmic reticulum 
proliferates and increases synthesis of lipids, presumably to regenerate the axonal 
membrane (Grafstein, 1975; Lieberman, 1971). Increased expression of mRNA encoding 
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growth-associated protein GAP-43, which is enriched in the growth cones of regenerating 
axons, co-localizes with FMN (Ide, 1996; Jones et al., 1997a). Cytoskeletal components 
important for longitudinal axon growth including βII-tubulin and actin increase in 
expression on both the mRNA (Hoffman & Cleveland, 1988; Jones et al., 1999; Tetzlaff 
et al., 1991) and protein levels (Tetzlaff et al., 1988a). Conversely, transcription and 
translation of neurofilament, which is important for radial axon growth, decreases after 
axotomy (Bisby & Tetzlaff, 1992; Hoffman & Cleveland, 1988; Tetzlaff et al., 1991; 
Tetzlaff et al., 1988a). Translation of proteins important for neurotransmission, such as 
neurotransmitter precursors and their modifying enzymes, also decreases (Grafstein, 
1975; Lieberman, 1971). 
 
2.1.3.2. Microglial response 
 Microglia proliferate within 1–4 days after axotomy (Graeber et al., 1988c; 
Torvik & Skjorten, 1971b). They increase expression of the motility-associated 
cytoskeletal protein vimentin and migrate toward the injured FMN, occupying 
perineuronal positions for at least the first week after injury (Graeber et al., 1988b; 
Graeber et al., 1988c). This migration may be mediated by complement receptor 3 (CR3), 
which is upregulated on microglia within 24 hours of axotomy (Graeber et al., 1988a; 
Svensson et al., 1993). Neuronal release of chemokine C-X3-C motif ligand 1 (CX3CL1, 
also known as fractalkine) may be another chemotactic signal via its cognate receptor 
CX3CR1 expressed on microglia (Harrison et al., 1998). FNA also induces expression of 
monocyte chemoattractant protein 1 (MCP-1, also known as CCL2) in FMN, which can 
trigger migration of microglia (Flugel et al., 2001). Despite (or perhaps due to) being 
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completely ensheathed by microglia, most neurons remain viable (Torvik & Skjorten, 
1971b). Microglia do not phagocytize neurons or their synaptic terminals at this time 
(Blinzinger & Kreutzberg, 1968). Eventually the perineuronal microglia migrate back 
into the neuropil, and their former positions are taken up by astrocytes (Graeber & 
Kreutzberg, 1988). However, activated microglia are still present in the FMNuc, instead 
forming clusters and phagocytizing neurons that have already degenerated (Torvik & 
Skjorten, 1971b). Microglia in the injured FMNuc increase their expression of MHC 
classes I and II, on which they may present antigen derived from degenerating neurons 
(Bohatschek et al., 2004; Streit et al., 1989b). 
 
2.1.3.3. Astrocyte response 
 Astrocytes in the FMNuc appear to increase in number by three days post 
axotomy, peak in number at 21 days, and may remain elevated for more than six months 
(Cammermeyer, 1955). However, this increase is not due to astrocyte proliferation, but 
rather due to local migration and hypertrophy (Graeber & Kreutzberg, 1986; Graeber et 
al., 1988c). After FNA, astrocytes undergo a non-mitotic transformation from a 
protoplasmic to a fibrous reactive type characterized by the presence of cytoplasmic 
filaments (Torvik & Skjorten, 1971b); (Graeber & Kreutzberg, 1986). Appearance of 
these filaments correlates with strong upregulation of glial fibrillary acidic protein 
(GFAP) mRNA and protein within 24 hours of axotomy (Jones et al., 1997b; Svensson et 
al., 1993; Tetzlaff et al., 1988b). This initial reaction is followed several weeks later by a 
second astrocyte transformation that is characterized by the appearance of thin, lamellar 
astrocyte processes covering the surfaces of injured motoneurons (Graeber & Kreutzberg, 
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1988). GFAP immunoreactivity resolves if target reconnection is allowed to occur, but 
may persist for a year or more if axon regeneration is mechanically blocked by a barrier 
(Laskawi & Wolff, 1996). This indicates that persistent loss of retrograde transport in 
neurons constitutes a signal for astrocyte activation. Unlike microglia, astrocytes do not 
express MHCI or MHCII in the FMNuc after axotomy (Streit et al., 1989b). 
 
2.1.3.4. Oligodendrocyte response 
 Considerably less attention has been given to the role of oligodendrocytes after 
axotomy. A transient increase in oligodendrocyte number has been observed at 3–5 days 
post FNA (Cammermeyer, 1955). However, several other studies report that there is no 
change in oligodendrocyte number or morphology due to injury (Barron et al., 1990; 
Torvik & Skjorten, 1971b).  
 
2.1.3.5. Synaptic stripping 
 Numerous electron microscopy studies have observed microglial processes 
extending along neuronal surfaces and separating UMN synaptic contacts from the 
injured LMN dendrites and soma after FNA (Blinzinger & Kreutzberg, 1968; Torvik & 
Skjorten, 1971b). Some studies note that after this initial reaction subsides, astrocyte 
processes interpose themselves between the microglia and FMN and continue to insulate 
neurons from synaptic input (Graeber & Kreutzberg, 1988; Svensson et al., 1993). In 
human postmortem tissue, astrocyte processes ensheathing injured FMN that have lost 
synaptic markers such as synaptophysin have also been observed (Graeber et al., 1993). 
Synaptic stripping and glial association with injured FMN are likely to be neuroprotective 
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mechanisms that shield injured FMN from excitotoxic inputs (Lopez-Redondo et al., 
2000). 
It is important to note that the interposition of glial processes between the pre- and 
post-synaptic neuron terminals does not necessarily represent active disruption of the 
synaptic structure, but rather may reflect opportunistic movement of glia into the negative 
space created by independent retraction of UMN axons and LMN dendrites (Grafstein, 
1975). Indeed, inhibiting microglial proliferation after hypoglossal axotomy has no effect 
on UMN synaptic retraction or subsequent peripheral nerve regeneration (Svensson & 
Aldskogius, 1993). Neuronal nitric oxide synthase (nNOS) activity increases after 
axotomy and is sufficient for synapse loss, suggesting that synaptic stripping is a 
motoneuron-autonomous process (Perry & O'Connor, 2010; Sunico et al., 2010). 
However, microglia do play a role in pathological forms of synaptic stripping that are 
implicated in neurodegenerative diseases such as Alzheimer’s disease (Rajendran & 
Paolicelli, 2018). 
 
2.1.4. Peripheral responses to axotomy 
 A tightly regulated peripheral response to axotomy occurs concomitantly with the 
central reaction of motoneurons and glia already discussed. Both innate and adaptive 







2.1.4.1. Wallerian degeneration 
 In 1850, neurophysiologist Augustus Waller described the degeneration of myelin 
and axons in the distal nerve segment after hypoglossal and glossopharyngeal nerve 
transection in frogs (Waller, 1850). The regulated sequence of events occurring in the 
distal nerve segment is now known as Wallerian degeneration. After axotomy, Schwann 
cells (SCs) de-differentiate and decrease their myelin synthesis (LeBlanc & Poduslo, 
1990). Rather than insulating axons, SCs proliferate and actively phagocytize myelin 
(Fernandez-Valle et al., 1995). They also secrete MCP-1/CCL2 and leukemia inhibiting 
factor (LIF) in an IL-6-dependent fashion, which together act as chemoattractant 
molecules for macrophages (Bolin et al., 1995; Tofaris et al., 2002). Macrophages in the 
vicinity then become activated, infiltrate the nerve, and phagocytize the degenerating 
nerve segment (Bruck, 1997; Perry et al., 1987). In the periphery, production of 
complement proteins is also important for macrophage participation in Wallerian 
degeneration. Failure of these innate immune responses to clear away debris after 
axotomy impedes subsequent axon regeneration (Dailey et al., 1998). 
 
2.1.4.2. Peripheral adaptive immune response 
 Along with the innate immune responses that are essential for Wallerian 
degeneration, adaptive immune responses also become activated after axotomy. Axotomy 
causes self-antigen (likely neuronal or myelin-derived) to drain into peripheral lymphoid 
tissues, and CD4+ T cells encounter this antigen on MHCII presented by APCs in the 
periphery (Byram et al., 2004). All major CD4+ T cell subsets investigated (Th1, Th2, 
Th17, Tr1, and Foxp3+ regulatory T cells) expand in the draining deep cervical lymph 
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nodes after FNA. Peak cellular expansion occurs by seven days post operation (dpo) and 
declines by nine dpo, indicating mobilization of T cells out of the lymph nodes (Xin et 
al., 2008). The generation of the adaptive immune response after axotomy is critical for 
neuroprotection and has been the focus of extensive study by our laboratory. 
 
2.1.5. Importance of the immune response after axotomy 
2.1.5.1. Immunodeficient mice have increased axotomy-induced FMN death 
 Investigation into the adaptive immune contribution to neuroprotection after FNA 
was first performed using severe combined immunodeficient (Scid) mice. These mice 
lack a DNA repair enzyme critical for V(D)J recombination to occur, resulting in failed 
generation of diverse B and T cell receptor repertoires. Whereas WT mice with normal 
immune systems do not show a statistically significant decrease in FMN survival after 
axotomy until 28 dpo, Scid mice show accelerated early neuronal loss, with significantly 
decreased FMN survival as early as 7 dpo (Serpe et al., 2000). By 28 dpo, FMN survival 
in Scid mice decreases to 52–55% of the control side, compared to WT mice which have 
85–87% FMN survival (Serpe et al., 1999; Serpe et al., 2000). FMN survival continues to 
decline in both WT and Scid through ten weeks post axotomy, although survival in Scid 
remains depressed relative to WT (45% compared with 60% FMN survival) (Serpe et al., 
2000). Furthermore, functional recovery is delayed after crush axotomy in Scid mice 
(Serpe et al., 2002). Nerve crush is a relatively mild injury that is permissive for target 
reconnection and causes minimal FMN death. The delayed recovery in Scid mice 
indicates that the adaptive immune system is necessary not only for FMN survival, but 
may also be important for FMN regenerative capacity. 
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 Because the Scid mutation produces defects in DNA repair, it could theoretically 
affect all cells in the body, not only the adaptive immune cells. Furthermore, it has been 
shown that the Scid mutation can become “leaky” as mice age (Bosma et al., 1988). This 
led to the adoption of the recombinase activating gene 2 knockout (RAG-2-/-) mouse 
model of immunodeficiency, in which V(D)J recombination is prevented in a more stable 
and specific manner. Similar to the Scid mouse, FMN survival is significantly decreased 
in the RAG-2-/-  mouse relative to WT at 28 dpo (64% versus 87% FMN survival) (Serpe 
et al., 2000). Reconstitution of either the Scid or RAG-2-/- immune system with WT 
whole splenocytes, which contain both B and T cells, restores FMN survival to WT levels 
(Serpe et al., 1999; Serpe et al., 2000). Because target reconnection would have occurred 
by approximately four weeks after axotomy under conditions ideal for regeneration 
(Kujawa et al., 1989), these data suggest that the adaptive immune system supports FMN 
survival during the early post-axotomy phase prior to target reconnection, after which 
target-derived NTF would presumably take the primary supportive role. However, this 
neuroprotective immune response cannot be sustained indefinitely if target reconnection 
is prevented. 
 
2.1.5.2. CD4+ T cells mediate neuroprotection after FNA 
 The adaptive immune milieu is a heterogenous cell population. To determine if a 
particular adaptive immune cell population is necessary for FMN survival, axotomy was 
superimposed on a variety of immunodeficient mouse models. Neither mice deficient for 
the immunoglobulin heavy constant μm (μMT mice), which lack mature B cells, nor   
Cd8-/- mice have decreased FMN survival after axotomy. However, Cd4-/- mice exhibit 
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decreased FMN survival after FNA similarly to what is seen in RAG-2-/- mice, indicating 
that the neuroprotective capacity of the adaptive immune system is specific to the CD4+ 
T cell. Furthermore, adoptive transfer of isolated CD4+ T cells is sufficient to rescue 
FMN survival in RAG-2-/- mice (Serpe et al., 2003). 
CD4+ T cells are themselves a diverse population and can be further subdivided 
into a number of T helper subsets that have differential expression of transcription factors 
and cytokines. Surprisingly, CD4+ T cells depleted of the CD25+ regulatory T cell 
subset, which exerts immunosuppressive and anti-inflammatory effects, are still capable 
of mediating neuroprotection. The CD4+CD1d-restricted NKT cell, which may be 
protective in experimental autoimmune encephalitis (EAE), is also not important for 
neuroprotection after FNA (DeBoy et al., 2006a; Teige et al., 2004). The importance of 
the Th1 and Th2 subsets for neuroprotection was assessed by performing FNA on mice 
deficient for signal transducer and activator of transcription (STAT)4, STAT6, interferon 
gamma (IFNγ), and IL-4. STAT4 is important for differentiation of the IFNγ-producing 
Th1 subset, and STAT6 is important for differentiation of the IL-4-producing Th2 subset. 
This series of experiments determined that Th2 cells and their associated cytokine IL-4 
are necessary for FMN survival after axotomy (Deboy et al., 2006b). Interestingly, mice 
lacking expression of Tbx21 (also known as T-BET), the Th1 master transcription factor, 
also have slowed functional recovery after nerve crush. This suggests that both Th1 and 
Th2 cells may be important for peripheral regeneration, while Th2 cells alone support 





2.1.5.3. Dynamics of T cell-mediated neuroprotection 
 In order for CD4+ T cells to effect their functions, they must presumably 
demonstrate specificity against antigen and migrate from the peripheral lymph nodes to 
the CNS. Chimeric mice that have MHCII expression restricted to either the central or 
peripheral compartments were employed to determine if the location of antigen 
presentation was important for CD4+ T cells to confer neuroprotection. Irradiated WT 
mice given H2ab1-/- (histocompatibility 2, class II antigen A, beta 1 knockout) bone 
marrow only express MHCII on central APC and have decreased FMN survival after 
axotomy unless given pre-activated, but not naïve, CD4+ T cells.  Irradiated H2ab1-/- 
mice given WT bone marrow only express MHCII in the periphery and also have 
decreased FMN survival after axotomy, although FMN survival in this mouse is not 
amenable to rescue by either naïve or pre-activated CD4+ T cells (Byram et al., 2004). 
These experiments show that CD4+ T cells must sequentially encounter MHCII 
expressed on peripheral and central APCs in order to confer neuroprotection. 
Furthermore, the central APC is most likely to be microglia, as they are resistant to 
irradiation unlike perivascular monocytes or infiltrating macrophages (Hickey & Kimura, 
1988). 
 Having encountered antigen presented on MHCII in the periphery, T cells must 
then migrate to the centrally-located APC. Th2-associated, but not Th1-associated 
chemokines increase by seven dpo in the axotomized FMNuc (Wainwright et al., 2009a). 
Pituitary adenylyl cyclase activating polypeptide (PACAP) is expressed by injured FMNs 
after axotomy and is capable of eliciting Th2-associated chemokine CCL11 expression 
by microglia in vitro (Armstrong et al., 2003; Wainwright et al., 2008). CCL11 is 
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expressed constitutively in FMN in vivo, but axotomy induces a shift in its expression 
from motoneurons to astrocytes (Wainwright et al., 2009c). Mice deficient for CCR3, a 
cognate receptor for CCL11, have decreased FMN survival after axotomy, and Ccr3-/- 
CD4+ T cells fail to confer neuroprotection in RAG-2-/- mice (Wainwright et al., 2009b). 
This indicates that axotomy induces production of chemotactic molecules in the FMNuc 
that enable recruitment of neuroprotective Th2 cells. 
 An illustrated summary of these proposed dynamics of CD4+ T cell-mediated 
neuroprotection is shown in Picture 1. 
 
2.1.5.4. Potential mechanisms of T cell-mediated rescue 
The overall extent of FMN death after axotomy is not uniformly distributed across 
the FMNuc, being more predominant in the lateral nuclei in the WT animal. The 
subpopulation of motoneurons that dies under conditions of immunodeficiency and is 
amenable to CD4+ T cell-mediated rescue is fairly evenly distributed across FMNuc 
subnuclei, although the dorsomedial subnucleus has the greatest FMN loss and recovery 
before and after immune cell reconstitution (Canh et al., 2006). This suggests that 
infiltrating T cells secrete an NTF that sustains FMN survival after injury. Brain-derived 
neurotrophic factor (BDNF) supports FMN survival in RAG-2-/- mice, but its production 
by CD4+ T cells is not necessary for neuroprotection (Serpe et al., 2005; Xin et al., 
2012). A crucial NTF produced by CD4+ T cells after FNA has not been identified. It is 
therefore possible that CD4+ T cells exert their neuroprotective effects through other 
mechanisms, such as by modulating the glial response to axotomy. This is supported by a 
recent finding that the inherent regenerative gene program in injured FMN is not altered 
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by immune status; rather, the CD4+ T cell is important for expression of genes associated 
with astrocytic and microglial activation (Setter et al., 2018b). 
 IL-10 is an anti-inflammatory cytokine that has received much attention in CNS 
research due to its pro-survival and glial-modulating effects (Lobo-Silva et al., 2016). IL-
10 is critical for FMN survival after axotomy. Although IL-10 derived directly from 
CD4+ T cells is not required after FNA, a source of IL-10 is necessary for CD4+ T cells 
to mediate their neuroprotective effects (Xin et al., 2011). This neuroprotective IL-10 
likely derives from a central source, as it cannot cross the blood-brain barrier (Kastin et 
al., 2003). Studies differ as to whether IL-10 levels increase or remain stable in the 
FMNuc after axotomy, but central expression of its receptor increases after FNA and 
localizes to neurons and/or astrocytes (Villacampa et al., 2015; Xin et al., 2011). IL-10 
may therefore have both trophic and glial-modulating roles in the FMNuc after FNA. 
 
2.2. Interleukin 10 
2.2.1. Discovery and characterization of IL-10 and its receptor 
 The discovery and early characterization of IL-10 is interwoven with those 
foundational studies in immunology that first supported the existence of different CD4+ 
T cell subsets. In 1971, Christopher Parish determined that T cells can mediate a delayed-
type hypersensitivity reaction in the absence of B cell interactions. For the first time, the 
generation of cell-mediated and antibody-mediated immunity were distinguished as 
separate and often antagonistic phenomena (Parish, 1971). These differential effects were 
later traced to the existence of two helper T cell subsets, Th1 and Th2, which Tim 
Mosmann and Robert Coffman functionally characterized in 1986 based on cytokine 
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production. They determined that Th1 cells produce IL-2 and IFNγ, and Th2 cells 
produce IL-3 and “mast cell growth factor” (later renamed IL-4) (Mosmann et al., 1986). 
Furthermore, these T cell subsets were capable of cross-regulation. The discovery that 
IFNγ produced by Th1 cells suppresses proliferation of Th2 cells directly supported 
Parish’s observations from the previous decade (Fernandez-Botran et al., 1988). Shortly 
thereafter followed the discovery of a new Th2-associated cytokine that suppresses Th1 
cytokine synthesis (Fiorentino et al., 1989). This Th2-associated suppressive cytokine 
was cloned in 1990 and renamed IL-10 (Moore et al., 1990). 
 Rapid characterization of the IL-10R soon followed these discoveries. The IL-
10R is a heterotetrameric type II cytokine receptor composed of two alpha and two beta 
subunits (Kotenko et al., 1997; Liu et al., 1994; Pestka et al., 2004). IL-10 binds as a 
dimer to the alpha subunit, and the beta subunit is consequently engaged for signaling 
(Pestka et al., 2004; Tan et al., 1993). Both receptor subunits are necessary for IL-10 
signal transduction (Kotenko et al., 1997). The IL-10R beta (IL-10RB) subunit is shared 
with some interferon receptors and other IL-10 family cytokine receptors. Despite this 
promiscuity, cells lacking IL-10RB respond normally to both type I interferons and IFNγ, 
but are completely unresponsive to IL-10 (Spencer et al., 1998). IL-10R alpha (IL-10RA) 
and IL-10RB recruit Janus kinase 1 (JAK1) and non-receptor tyrosine-protein kinase 
(TYK2), respectively. Following their autophosphorylation, these kinases recruit STAT 
proteins that translocate to the nucleus to regulate transcriptional events. IL-10 is known 
to increase transcription of suppressor of cytokine signaling (SOCS)1 and SOCS3, which 
inhibit NF-κB and downstream cytokine production. IL-10 signaling also increases 
expression of mitochondrial proteins Bcl-2 and Bcl-xL, which inhibit cytochrome c 
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release and subsequent apoptosis (Moore et al., 2001; Pestka et al., 2004). Other pro-
survival and proliferative pathways activated by IL-10 include PI3K/AKT and 
MAPK/ERK. IL-10 inhibits pro-apoptotic kinases including JNK and p38 MAPK (Strle 
et al., 2001).  
 
2.2.2. Characterization of IL-10 function in periphery 
 Loss of IL-10 leads to the development of spontaneous enterocolitis due to 
uncontrolled cell-mediated autoimmunity (Kuhn et al., 1993). Loss of only the IL-10RB 
subunit is sufficient to replicate this phenotype (Spencer et al., 1998). The dramatic 
increases in inflammation seen in these disease models support the role of IL-10 as an 
important regulator of immune responses in the periphery. In addition to Th2 cells, other 
common peripheral sources of IL-10 include regulatory T cells (Tregs), 
monocytes/macrophages, and dendritic cells. Many additional cell types, such as 
cytotoxic T cells, natural killer cells, B cells, mast cells, neutrophils, eosinophils, and 
epithelial cells can also make IL-10 under special conditions (Iyer & Cheng, 2012). 
 One of the earliest characterized roles of IL-10 in the periphery was the inhibition 
of Th1-secreted cytokine production, as has been described previously (Fiorentino et al., 
1989). IL-10 was found to have this effect mainly by its actions on macrophage and 
dendritic APCs (Fiorentino et al., 1991b). IL-10 suppresses the production of pro-
inflammatory cytokines by APC (particularly monocytes/macrophages) that are 
responsible for both Th1 activation and acute inflammatory responses. Th2 responses are 
not significantly affected by this mechanism (Fiorentino et al., 1991a). In fact, IL-10-
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primed dendritic cells may preferentially promote Th2 subset differentiation (Liu et al., 
1998).  
IL-10 also inhibits the ability of APC to participate in antigen presentation and T 
cell co-stimulation by decreasing expression of MHCII and CD80/86 (also known as 
B7.1/7.2) (de Waal Malefyt et al., 1991; Ding et al., 1993; Ding & Shevach, 1992). 
Through these mechanisms, IL-10 is capable of converting immature dendritic cells into 
“tolerogenic” APCs that promote CD4+ T cell anergy (Steinbrink et al., 1997). IL-10 also 
tends to favor the development of humoral, rather than cell-mediated, immunity by 
promoting B cell differentiation and proliferation (Itoh & Hirohata, 1995). Unlike 
macrophages and dendritic cells, the antigen-presenting ability of B cells is not affected 
by IL-10 (Fiorentino et al., 1991b). 
Although IL-10 was originally believed only to act on T cells indirectly via the 
APC, it was later determined that IL-10 can indeed have direct effects on T cells. IL-10 
directly inhibits T cell proliferation via suppression of IL-2 signaling (de Waal Malefyt et 
al., 1993). IL-10 also directly suppresses T cell activation and cytokine secretion that is 
dependent on CD28-CD80/86 interactions (Schandene et al., 1994; Taylor et al., 2006). It 
has this effect by blocking CD28 phosphorylation and PI3K binding in T cells (Akdis et 
al., 2000; Joss et al., 2000). Inhibition of CD28 in T cells may be downstream of IL-
10RB and TYK2 activation specifically (Verma et al., 2016). Loss of CD28 co-
stimulation results in specific T cell tolerance to antigen (Akdis & Blaser, 2001). Anergic 
T cells may be capable of inhibiting antigen presentation by dendritic cells and 
suppressing the proliferation of other T cells in an antigen-specific and contact-dependent 
fashion (Chai et al., 1999; Vendetti et al., 2000). 
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2.2.3. Potential roles of IL-10 in the CNS  
Based on the signaling pathways and mechanisms described above, IL-10 can 
theoretically promote neuroprotection in three ways: 1) suppression of pro-inflammatory 
cytokine secretion from monocytes/macrophages (which may include CNS microglia); 2) 
suppression of cellular autoimmunity through inhibition of MHCII and co-stimulatory 
molecule expression on APCs and CD28 transduction in T cells; and/or 3) direct 
promotion of pro-survival and suppression of pro-apoptotic pathways in neurons. While 
studies that employ exogenous application of IL-10 in the CNS produce interesting 
insights into the neuroprotective capacity of IL-10, such insights may represent non-
physiologically relevant mechanisms of IL-10 function. Important clues about the role of 
IL-10 in the CNS are perhaps better afforded by studying endogenous IL-10 production 
as well as the consequences of IL-10 reduction or elimination in the context of injury or 
disease.  
Loss of endogenous IL-10 is associated with increased neuroinflammation, 
cerebral edema, and intracerebral hemorrhage in Listeria monocytogenes brain infections, 
possibly due to over-recruitment of peripheral lymphocytes into central tissues (Deckert 
et al., 2001). Endogenous IL-10 limits cerebral ischemia-induced infarct volume in vivo 
and protects primary cortical neurons against death due to excitotoxicity and oxygen-
glucose deprivation in vitro (Grilli et al., 2000). T cells are likely involved in this process, 
as the success of myelin peptide immunization in reducing ischemic infarct volume after 
middle cerebral artery occlusion is dependent on IL-10-producing CD4+ T cells (Frenkel 
et al., 2005). Regulatory T cells also have beneficial effects on inflammation and neuron 
survival after hemorrhagic stroke, in which they modulate microglial polarization via IL-
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10 production (Zhou et al., 2017). Suppressed IL-10 production by Tr1 regulatory T cells 
and decreased CD4+ T cell responsiveness to IL-10 are observed in patients with 
multiple sclerosis (MS) (Martinez-Forero et al., 2008). First-degree family members of 
patients with MS are at greater risk of developing disease if their innate production of IL-
10 is low (de Jong et al., 2000). Enhancing the induction of Trl regulatory T cells limits 
neuroinflammation in a mouse model of MS by reducing glial activation, suppressing 
recruitment of peripheral lymphocytes, and preserving blood-brain barrier integrity in an 
IL-10 dependent manner (Mayo et al., 2016).  
In addition to T cell production of IL-10, microglial production of IL-10 in 
response to inflammatory stimuli is also important for neuroprotection. In vivo 
lipopolysaccharide (LPS) challenge promotes IL-10 production by microglia, and 
blocking this IL-10 signaling increases neuronal death and production of pro-
inflammatory mediators including IL-1β, tumor necrosis factor alpha (TNFα), and 
reactive oxygen species (Park et al., 2007). In the SOD1G93A mouse model of ALS, 
blocking IL-10 signaling causes an increase in microglial activation in the spinal cord and 
precipitates the onset of disease symptoms, although lifespan is not affected (Gravel et 
al., 2016). Overall, these studies indicate that endogenous IL-10, frequently produced by 
CD4+ T cells and microglia, is important for CNS health by modulating inflammatory 
activation of glia, limiting the recruitment of peripheral immune cells to central tissues, 




2.3. Aims of this study 
2.3.1. Aim 1: Determine the central cellular sources of IL-10 in the facial motor nucleus 
and the respective contributions of these sources to motoneuron survival after axotomy 
 IL-10 is necessary for CD4+ T cells to mediate neuroprotection after FNA, but 
CD4+ T cells are not the requisite source of IL-10 in the FMNuc. Additionally, IL-10 
applied directly to the proximal nerve stump, which lies outside of the CNS, does not 
improve FMN survival (Xin et al., 2011). These data suggest that a central source of IL-
10 is necessary for neuroprotection. This hypothesis is supported by the fact that IL-10 
cannot cross the blood-brain barrier (Kastin et al., 2003). However, it is possible that the 
neuroprotective role of IL-10 is purely due to its ability to favor the development of Th2 
rather than Th1 responses in the context of antigen presentation in the peripheral lymph 
nodes (Fiorentino et al., 1991a; Liu et al., 1998). Only Th2 cells are neuroprotective after 
axotomy (Deboy et al., 2006b). Therefore, IL-10 production both by peripheral APC as 
well as by central cells in the FMNuc such as microglia, neurons, and astrocytes must be 
evaluated. 
 In CNS injury and disease, neuroprotective IL-10 production is typically 
associated with regulatory T cells and microglia (see section 2.2.3). Because an IL-10 
contribution from T cells has been ruled out in the FNA model, microglia are the most 
likely source of IL-10 in the FMNuc (Xin et al., 2011). Microglia are known to produce 
IL-10 in response to a number of inflammatory stimuli (Gravel et al., 2016; Jack et al., 
2005; Ledeboer et al., 2002; Seo et al., 2008). Additionally, Th2 cells produce IL-4, 
which promotes the polarization of microglia toward the “M2” anti-inflammatory 
phenotype characterized in part by IL-10 production (Chabot et al., 1999; Chhor et al., 
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2013; Zhang et al., 2014) Therefore, the hypothesis for this aim is that microglia are the 
obligate source of neuroprotective IL-10 after axotomy. This hypothesis will be tested 
using a combination of IHC localization and Cre/Lox recombination to reduce IL-10 
expression in a cell-specific manner. 
 
2.3.2. Aim 2: Characterize adaptive immune cell participation in neuroprotective IL-10 
receptor signaling after facial nerve axotomy 
 FMN survival after axotomy is dependent on both CD4+ T cell-mediated and IL-
10-mediated mechanisms. Although CD4+ T cells are not responsible for IL-10 
production after FNA, it is not known whether they regulate downstream IL-10 signaling. 
Neuroprotective actions of IL-10 after FNA are likely effected through increased 
expression of the IL-10R (Xin et al., 2011), which may be mediated by CD4+ T cells. 
IHC will be performed to determine whether CD4+ T cells are capable of interacting 
directly with central cells in the FMNuc to influence their gene expression. qPCR 
analysis will be performed in WT and RAG-2-/- mice to determine whether the adaptive 
immune system is necessary for IL-10R subunit expression in the FMNuc after axotomy. 
Because IL-10 can have direct actions on T cells, the ability of IL-10R-deficient CD4+ T 
cells to regulate central IL-10R expression and confer neuroprotection will also be 
assessed. The hypothesis for this aim is that CD4+ T cells are necessary for central IL-10 
receptor expression and must respond to IL-10 themselves to confer neuroprotection. 
Loss of IL-10R signaling on T cells may result in failed acquisition of tolerance to self-
antigen (Akdis & Blaser, 2001). This possibility will be explored via analysis of genes 
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associated with inflammatory immune activation, including general microglial activation 





Picture 1: Schematic illustrating hypothesized dynamics of CD4+ T cell-mediated 
neuroprotection. 
 
1) After FNA, an unknown antigen (potentially neuronal, myelin-derived, or glial in 
origin) drains into the deep cervical lymph nodes, is taken up and processed by peripheral 
APCs (likely dendritic cells), and displayed on their MHCII. 2) Peripheral CD4+ T cells 
recognize antigen displayed on MHCII and undergo clonal expansion. 3) Attracted by 
chemokines such as CCL11 produced by astrocytes, CD4+ T cells migrate to the FMNuc. 
4) CD4+ T cells encounter antigen and MHCII on a centrally located APC, likely 
microglia. T cell encounter with MHCII in both the peripheral and central compartments 
is necessary for neuroprotection. 
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CHAPTER 3: MATERIALS AND METHODS 
 
3.1. Animals used in this study 
 See Table 1 for a list of animal strains used in this study. For animals obtained 
from The Jackson Laboratory, only female mice were used due to the tendency of male 
non-littermates to engage in fighting behavior after axotomy, leading to infections at the 
surgery site. These animals were obtained at six or seven weeks of age and allowed to 
acclimate for at least one week prior to use. For animals bred in house (IL10flox/flox strain 
crossed with all Cre-expressing strains), equal numbers of male and female mice were 
used in experiments. Mice were housed in sterilized microisolater cages equipped with a 
laminar flow system to maintain a pathogen-free environment and allowed access to 
autoclaved food pellets and water ad libitum. IL-10-/- and Il10rb-/- mice were also given 
access to wet food to prevent possible complications from the development of 
enterocolitis, although no symptoms of enterocolitis (such as loss of body weight) were 
noted in any animals during the duration of the study. Animal rooms operated on a 12 
hour light/dark cycle. All animal procedures complied with National Institutes of Health 
guidelines on the care and use of laboratory animals and were approved by the 
Institutional Animal Care and Use Committee at Indiana University School of Medicine.  
 
3.2. Preparation of genomic DNA and polymerase chain reaction (PCR) 
 Genomic DNA was extracted from tail snips (for genotyping) and spleen (to 
confirm adoptive transfer engraftment) using Gentra® PureGene® Core Kit A (QIAGEN 
Sciences, cat. no. 1042601) following manufacturer instructions. PCR was performed on 
genomic DNA using primers listed in Table 2 and illustra™ PuReTaq Ready-To-Go™ 
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PCR Beads (GE Life Sciences, cat. no. 27955701). PCR amplicons were run on a 1.5-2% 
agarose gel at 120-150 V for 20–40 minutes and were subsequently imaged using a Cell 
Biosciences FluorChem E system. 
PCR for IL10 exon 1 yielded a 133 base pair (bp) sequence in WT. PCR for IL10 
floxed sequence and exon 2 yielded a 480 bp sequence in WT and 514 bp sequence in 
floxed animals. All IL10 PCR was performed using the following program: 95°C for 2 
min; 30 cycles of 95°C for 30 sec, 60° for 45 sec, 72°C for 45 sec; and 72°C for 5 min.  
PCR for Thy1Cre yielded a 300 bp sequence in animals expressing Cre 
recombinase under control of the Thy1 promoter. PCR for GfapCre yielded a 200 bp 
sequence in animals expressing Cre recombinase under control of the Gfap promoter. 
PCR for Cx3cr1Cre yielded a 300 bp sequence in animals expressing Cre recombinase 
under control of the Cx3cr1 promoter. All Cre PCR was performed using the following 
program: 94°C for 2 min; 10 cycles of 94°C for 20 sec, 65°C for 15 sec with -0.5°C per 
cycle decrease, 68°C for 10 sec; 28 cycles of 94°C for 15 sec, 60°C for 15 sec, 72°C for 
10sec; and 72°C for 2 min. 
 
3.3. Adoptive transfer 
 Donor animals were utilized at a 1:1 ratio to recipients. Following CO2 euthanasia 
and cervical dislocation, spleens were removed and placed in 1–2 mL cold working 
buffer (0.5% BSA + 2 mM EDTA in 1X PBS). Spleens were mechanically dissociated 
using the back of a sterile syringe, and the cell suspensions were filtered through a 70 μm 
cell strainer and pelleted via centrifugation for 10 min at 350 g. When adoptive transfer 
of whole splenocytes was desired, the cell pellet was resuspended in 1 mL red blood cell 
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lysis buffer (150 mM NH4Cl + 10 mM KHCO3 + 0.1 mM EDTA in ddH2O) and left to 
rest for 5 min at room temperature prior to leveling up with cold working buffer and 
centrifugation for 10 min at 350 g. When adoptive transfer of isolated CD4+ T cells was 
desired, pellets were resuspended in 90 μl working buffer/107 cells. 10 μl CD4 magnetic 
beads (Miltenyi Biotec, cat. no. 130-117-043)/107 cells were added and cells were 
incubated for 10 min on ice. Cells were manually sorted using LS columns (Miltenyi 
Biotec, cat. no. 130-042-401) following manufacturer instructions. The eluent was then 
passed through a new column a second time to enhance cell purity. Flow cytometry 
revealed sorted CD4+ T cell purity to be 96% (data available upon request).  Cells were 
resuspended in working buffer for counting and subsequently washed with 1X PBS. Cells 
were resuspended in a suitable volume of 1X PBS to yield 50∙106 whole splenocytes or 
5∙106 sorted CD4+ T cells per 100 μl injection. Recipient mice received donor cells via 
tail vein injection one week prior to FNA to allow for engraftment of transferred cells. 
 
3.4. Induction of Cre recombinase 
 For Cre/Lox experiments, animals expressing at least one copy of Cre 
recombinase and homozygous for floxed IL-10 sequences (Cre+/+IL10fl/fl or Cre+/-IL10fl/fl) 
were used in the experimental group. Animals negative for either Cre or floxed IL-10 
sequences (Cre-/-IL10any or CreanyIL10wt/wt) were used as littermate controls. One week 
prior to axotomy (seven weeks of age), animals in both groups were given once daily 
intraperitoneal injections of 75 mg/kg tamoxifen (Sigma-Aldrich, cat. no. T5648-5G) 
suspended in corn oil (Sigma-Aldrich, cat. no. C8267) at a concentration of 20 mg/mL 
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for five consecutive days. To maintain Cre expression, injections were administered on a 
biweekly basis until euthanasia.  
 To evaluate extent of IL-10 knockdown, mice were given once daily 
intraperitoneal injections of tamoxifen for five consecutive days, followed by one week 
of biweekly injections. Two weeks after tamoxifen induction of Cre was started, LPS was 
injected at 5 mg/kg to stimulate IL-10 production in glia. LPS was not administered to 
animals used for evaluation of neuronal IL-10 production. Animals were euthanized at 
either 3 h (for evaluation of microglia) or 12 h (for astrocytes) post LPS injection. 
Following euthanasia and brain removal, brains were dissociated using the MACS 
Neural Tissue Dissociation Kit (P) (Miltenyi Biotec, cat. no. 130-092-628) following 
manufacturer’s protocol for manual dissociation, and cells were sorted using anti-CD11b 
(Miltenyi Biotec, cat. no. 130-093-634), anti-GLAST (130-098-803), or neuron isolation 
kit (130-115-390) microbeads per manufacturer instructions. Sorted cells were pelleted, 
washed with PBS, and lysed with Pierce™ RIPA Lysis and Extraction Buffer (Thermo 
Scientific™, cat. no. 89900). Protein concentration was determined using a Pierce™ 
BCA Protein Assay Kit (Thermo Scientific™). For evaluation of IL-10 in glia, 25–100 
ng protein was blotted onto a nitrocellulose membrane and probed with rat anti-mouse 
IL-10 antibody (Invitrogen, cat. no. 12-7101-81) at 1:1000 dilution followed by goat anti-
rat HRP (Abcam, cat. no. ab97057) at 1:25000 dilution. HRP signal was detected using 
GE Healthcare Amersham™ ECL™ Prime Western Blotting Detection Reagent (Fisher 
Scientific, cat. no. 45-002-401) following manufacturer instructions. Integrated density 
measurements were performed on dot blot images in ImageJ. IL-10 in microglia was 
determined to be 14–34% reduced in cKO compared to littermate controls, and IL-10 in 
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astrocytes was determined to be 51-83% reduced (data available upon request). For 
evaluation of IL-10 in neurons, protein lysates were analyzed using a Mouse IL-10 
ELISA MAX™ Deluxe kit (BioLegend, cat. no. 431414). IL-10 was reduced by 
approximately 27% in neurons isolated from cKO animals compared to littermate 
controls (data available upon request). 
 
3.5. Facial nerve axotomy 
FNA was performed when mice were eight weeks old. The detailed surgical 
procedure has been published previously (Olmstead et al., 2015). Briefly, animals were 
anesthetized with 2.5% isoflurane in oxygen at a flow rate of 0.9 L/min. The incision site 
was wetted with 70% ethanol, shaved, and alternately swabbed with 70% ethanol and 
iodine solution three times. All surgical instruments were sterilized prior to use. Using 
aseptic techniques, a small (~4 mm) incision was made just posterior to the ear 
protuberance. The underlying fascia was dissected bluntly until the facial nerve was 
visible. The facial nerve was traced posteriorly and severed just distal to its emergence 
from the stylomastoid foramen, taking care not to apply traction to the nerve to avoid its 
avulsion from the brainstem. The distal nerve stump was either pushed away from the 
proximal stump, or a small segment of the distal nerve stump was resected to prevent 
reconnection. The wound site was closed with a metal wound clip, which was removed 
between 7–10 days after surgery. Following surgery, successful transection of the facial 




3.6. Motoneuron counting 
 For motoneuron counting, animals (n = 3–6) were euthanized at 28 dpo using CO2 
inhalation and cervical dislocation. Brains were removed and flash-frozen at the interface 
of a pre-chilled 37.5% 2-methylbutane/62.5% 1-bromobutane biphasic solution on dry ice 
for at least five minutes. Frozen brains were stored at -80°C. One hour prior to 
sectioning, brains were thawed at -20°C and embedded in optimum cutting temperature 
(OCT) medium. Brainstem sections spanning the caudal-rostral extent of the FMNuc 
were cryosectioned at 25 μm, collected onto Superfrost Plus slides (Thermo Scientific), 
and stored at -20°C. For thionin staining, sections were fixed in 4% paraformaldehyde 
(PFA) for 15 min and washed 2x5 min in ddH2O. Sections were stained in working 
thionin solution (described below) for 15 min and dipped in ddH2O for 30 sec, followed 
by dehydration in a 50%, 70%, 95%, 100% ethanol series for 30 sec each. Sections were 
cleared in CitriSolv overnight or up to three days and subsequently coverslipped using 
Permount toluene-based mounting medium. 
 For counting, an impartial investigator coded all slides. A separate blinded 
investigator used a Leica DMRB light microscope and Neurolucida software (version 
10.31) to manually count motoneurons in the FMNuc. To avoid double-counting, only 
FMN profiles with a nucleus and nucleolus were counted. Mean percentage FMN 
survival was quantified by dividing the total number of FMN on the axotomized side by 
the total number on the control side and multiplying by 100%. A student’s t-test was 
performed for experiments containing ≤2 groups, and one-way analysis of variance 
(ANOVA) followed by a Student-Newman-Keuls post-hoc test was performed for 
experiments containing ≥2 groups with an alpha of 0.05. 
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 To prepare thionin staining solutions, a stock solution of 1% thionin acetate 
(Sigma Aldrich, cat. no. 861340) was prepared in ddH2O, stirred overnight, and filtered. 
Acetate buffer was prepared by mixing 180 mL 1 M glacial acetic acid and 20 mL 
sodium acetate and adjusting pH to 3.5. To prepare the working thionin solution, 38 mL 
thionin stock was combined with 200 mL acetate buffer and 560 mL ddH2O. 
 
3.7. Immunohistochemistry 
3.7.1. IL-10/GFP reporter 
 For IL-10/green fluorescent protein (GFP) reporter mice (n = 3/time point), brains 
were removed and flash-frozen as described in section 3.6. Various time points (3, 7, 10, 
14, and 28 dpo) were used. Brainstem sections spanning the caudal-rostral extent of the 
FMNuc were cryosectioned at 8 μm, collected onto Superfrost Plus slides (Thermo 
Scientific), and stored at -20°C. Sections were fixed in 4% PFA for 15 minutes and 
washed 3x5 minutes in PBS. Sections were blocked in 10% donkey serum, 1% BSA, and 
0.01% Triton X-100 in PBS for one hour prior to incubation with primary antibodies (see 
Table 3 for antibodies and concentrations used) diluted in the same blocking medium 
overnight at 4°C. Sections were washed 3x5 minutes in PBS prior to incubation with 
secondary antibody for 1 h at room temperature. Excess secondary antibody was removed 
with 3x5 min washes in PBS, and slides were mounted with DAPI Fluoromount-G® 
(Southern Biotech, cat. no. 0100-20). Images were captured with an Olympus BX50 
inverted fluorescent microscope using Olympus cellSens Entry 1.9 software, and 




3.7.2. Immunohistochemistry performed on wild-type tissue 
Animals (n = 3/time point) were euthanized at 3, 7, 10, 14, and 28 day time points 
via ketamine-xylazine overdose and exsanguination followed by perfusion with 2% 
buffered PFA. Brains were removed, post-fixed in 2% PFA 1 h, and equilibrated in 30% 
sucrose. Brains were embedded in OCT medium, and 8 μm brainstem sections containing 
the FMNuc were collected. Sections were first blocked for 1 h at room temperature in 
10% donkey serum, 1% bovine serum albumin, and 0.01% Triton X-100 in PBS, 
followed by incubation in primary antibody (see Table 3) for 2 h at room temperature or 
16 h at 4°C. Secondary staining and imaging proceeded as described in section 3.7.1. 
When fluorescent Nissl staining was desired, NeuroTrace™ 435/455 Blue Fluorescent 
Nissl Stain (Thermo Fisher, cat. no. N21479) was diluted 1:100 in PBS, applied to 
sections for 20 min after removing the secondary antibody, and washed 3x5 min in PBS 
prior to mounting in ProLong™ Gold Antifade medium (Invitrogen, cat. no. P36930). 
 
3.8. Fluorescent in situ hybridization 
For FISH, care was taken to use only reagents prepared in DEPC-treated H2O to 
avoid RNase contamination. Animals (n = 3/time point) were euthanized, and brains were 
removed, flash-frozen, and sectioned at 8 μm as described in section 3.6. FISH was 
performed using Stellaris® RNA FISH probes (LGC Biosearch Technologies) following 
manufacturer’s instructions available online at www.biosearchtech.com/stellarisprotocols 
with the following changes. Sections were fixed for 4 h in 4% PFA, washed 2x10 min in 
PBS, dipped in H2O, and equilibrated in 1X triethanolamine (TEA) buffer for 10 min. 
Next, slides were immersed in 1X TEA + 0.25% acetic anhydride for 10 min (stirring) 
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and washed in 2X SSC for 10 min. Slides were then dehydrated following the Stellaris® 
protocol. After air drying, slides were hybridized with 1000 nM Stellaris® RNA FISH 
probes diluted in Stellaris® hybridization buffer in a humidified chamber at 55°C 
overnight. Ready-made probes were used for Cx3cr1 Quasar® 570 (cat. no. VSMF-3102-
5), and custom probes for Il10 Quasar® 670 were designed using the Stellaris® FISH 
Probe Designer for sequence NM_010548.2. Day 2 of the protocol followed 
manufacturer’s instructions, with the exception of using DAPI Fluoromount-G® 
(Southern Biotech) mounting medium instead of separate DAPI labeling and slide 
mounting. Imaging was performed using a Nikon A1 confocal microscope, and post-
processing to remove background was performed in ImageJ. 
 
3.9. Laser capture microdissection (LCM) 
 Brains were removed and flash-frozen as described in section 3.6. 25 μm sections 
spanning the FMNuc were collected onto PEN membrane slides (Leica Microsystems, 
cat. no. 11505158). Slides were stored at -80°C until ready to use. For staining and 
lasering, care was taken to use only reagents prepared in DEPC-treated H2O to avoid 
RNase contamination. Slides were thawed at -20°C for one hour prior to LCM and were 
removed and processed one at a time. Each slide was stained with the following series: 1 
min 100% ethanol, 2x15 sec H2O, 30 sec thionin stain (4X thionin concentration as 
described in section 3.6), 2x15 sec H2O, 20 sec 70% ethanol, 20 sec 90% ethanol, 20 sec 
100% ethanol. Slides were air-dried 1–2 min after staining. A Leica ASLMD microscope 
was used to collect the right and left FMNuc into tubes containing 60 μl RNA extraction 
buffer (Arcturus PicoPure® RNA Isolation Kit, Applied Biosystems, cat. no. KIT0204). 
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Tubes were incubated at 42°C for 30 min, centrifuged at 800 g for 2 min, and stored at     
-80°C until RNA extraction. 
 
3.10. RNA extraction and reverse transcription (RT) 
 RNA was extracted from LCM samples following the Arcturus PicoPure® RNA 
Isolation Kit protocol with an elution volume of 14 μl. For the spleen standard used for 
Tnf qPCR, RNA was extracted from WT spleen tissue using the QIAGEN RNeasy Mini 
Kit (cat. nos. 74104 and 74106) and QIAGEN RNase-Free DNase Set (cat. no. 79254) 
following manufacturer instructions. RNA was quantified using a NanoDrop 2000 
spectrophotometer and stored at -80°C until RT. 60 ng of RNA was used for RT, which 
was performed using SuperScript® VILO Master Mix (Invitrogen, cat. no. 11755050) 
following the manufacturer’s protocol. cDNA was stored at -20°C until ready for qPCR. 
 
3.11. qPCR 
 Reaction volumes for qPCR used 1 μl cDNA, 1 μl TaqMan® FAM gene 
expression assay (see Table 4), 10 μl TaqMan Gene Expression Master Mix (Thermo 
Fisher, cat. no. 4369016), and 8 μl RNase-free H2O. qPCR was performed using a Bio-
rad Bio-Plex® 200 real-time PCR system using the following program: 50°C for 2 min, 
95°C for 10 min, 40 cycles of 95°C for 15 sec and 60°C for 1 min. To maintain 
consistency with previous studies using custom-made primers for Cd68, the following 
custom TaqMan primers and probes were ordered: F 5’-
CCCAAATTCAAATCCGAATCC-3’, R 5’-GGTACCGTCACAACCTCC-3’, probe 5’-
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AAAGTGAGTGCGTCCCTTGCAGCC-3’. All other probes are commercially available 
and are listed in Table 4. 
 CT values were normalized to the reference gene Gapdh and the percent and fold 
changes in mRNA expression between axotomized and control FMNuc were calculated 
following the Pfaffl method (Pfaffl, 2001). Because Tnf is only expressed on the 
axotomized FMNuc, the ΔΔCT value was calculated using a spleen cDNA standard, and 
its levels in axotomized FMNuc are expressed relative to WT spleen. The same spleen 
standard was used for comparison across all samples. Outliers were detected using the 
Grubbs’ test (also called extreme studentized deviate method). One-way ANOVA 
followed by Student-Newman-Keuls multiple comparisons or two-way ANOVA 
followed by Bonferroni multiple comparisons (as applicable depending on number of 
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B6.129P2-Il10tm1Cgn/J IL-10-/- The Jackson Laboratory 
B6.129S2-Il10rbtm1Agt/J Il10rb-/- The Jackson Laboratory 
B6.Cg-Tg(GFAP-
cre/ERT2)505Fmv/J 
GfapCre The Jackson Laboratory 
C57BL/6J WT The Jackson Laboratory 
IL10flox/flox  Dr. Gang Huang, Cincinnati 
Children’s Hospital; see Roers 
et al. (2004) 
Tg(Thy1-cre/ERT2,-
EYFP)HGfng/PyngJ 
Thy1Cre The Jackson Laboratory 




Gene 5’ primer sequence 3’ primer sequence 
IL10 exon 1 (133 bp in WT) ATG CCT GGC TCA G CCA CAT GCT CCT 
AGA GCT GC 
IL10 floxed sequence and 
exon 2 (480 bp WT, 514 bp 
floxed) 
CCA GCA TAG AGA 
GCT TGC ATT ACA 
GAG TCG GTT AGC 
AGT ATG TTG TCC 
AG 
Thy1Cre transgene (300 bp) TCT GAG TGG CAA 
AGG ACC TTA GG 
CGC TGA ACT TGT 
GGC CGT TTA CG 
Thy1Cre internal control (200 
bp) 
CAA ATG TTG CTT 
GTC TGG TG 
GTC AGT CGA GTG 
CAC AGT TT 
GfapCre transgene (200 bp) GCC AGT CTA GCC 
CAC TCC TT 
TCC CTG AAC ATG 
TCC ATC AG 
GfapCre internal control (324 
bp) 
CTA GGC CAC AGA 
ATT GAA AGA TCT 
GTA GGT GGA AAT 
TCT AGC ATC ATC C 
Cx3cr1Cre transgene (300 bp) AAG ACT CAC GTG 
GAC CTG CT 
CGG TTA TTC AAC 
TTG CAC CA 
Cx3cr1Cre internal control (695 
bp) 
AAG ACT CAC GTG 
GAC CTG CT (common) 
AGG ATG TTG ACT 
TCC GAG TTG 




Primary antibodies Manufacturer and Catalog 
Number 
Dilution 
Mouse anti-GFAP 594 (used in IL-10/GFP 
reporter) 
Thermo Fisher A-21295 1:500 
Rabbit anti-GFP 488 Thermo Fisher A-21311 1:100 
Rabbit anti-IBA1 Thermo Fisher 019-19741 1:500 
Mouse anti-NeuN 555  Millipore MAB377A5 1:200 
Rabbit anti-GFAP (used in perfused WT 
tissue) 
Thermo Fisher PA3-16727 1:1000 
Goat anti-IL-10 R&D Systems AF519 1:200 
Rat anti-CD4 488 Biolegend 100423 1:100 
Rabbit anti-CD3 Abcam ab16669 1:200 
Rabbit anti-CD31 Abcam ab124432 1:500 
   
Secondary antibodies Manufacturer and Catalog 
Number 
Dilution 
Donkey anti-rabbit 568 (used for GFAP, 
IBA1, CD3, CD31) 
Abcam ab175470 1:1000 
Donkey anti-goat 488 (used for IL-10) Abcam ab150129 1:1000 
Donkey anti-rat 488 (used for CD4) Thermo Fisher A21208 1:1000 





Gene TaqMan ID RefSeq Accession Number 
B2m Mm00437762_m1 NM_009735.3 
C3 Mm01232779_m1 (GenBank–no RefSeq numbers available) 
BC029976.1, BC043338.1, DQ408205.1, EU868829.1, 
HM856604.1, K02782.1 
Cd40 Mm00441891_m1 NM_011611.2, NM_170702.2,  
NM_170703.2, NM_170704.2, NR_027852.1 
Cd80 Mm00711660_m1 NM_009855.2 
Cd86 Mm00444543_m1 NM_019388.3 
Gapdh Mm99999915_g1 NM_001289726.1, NM_008084.3 
H2ab1 Mm00439216_m1  NM_207105.3 
Nos2 Mm00440502_m1 NM_010927.3 
Tnfrsf1 Mm00441883_g1 NM_011609.4 
Tnfα Mm00443260_g1 NM_013693.3 




CHAPTER 4: RESULTS 
 
4.1. Aim 1: Determine the central cellular sources of IL-10 in the facial motor 
nucleus and the respective contributions of these sources to motoneuron survival 
after axotomy  
4.1.1. Contribution of IL-10 from peripheral immune cells to central facial motoneuron 
survival 
 Previous studies have shown that although IL-10 is necessary for CD4+ T cells to 
mediate neuroprotection, CD4+ T cells themselves are not the required IL-10 producers 
in this injury model (Xin et al., 2011). Prior to operating under the assumption that the 
source of neuroprotective IL-10 must be centrally located, it was first essential to 
eliminate other peripheral sources of IL-10, such as APCs, as potential candidates. This is 
due to the possibility that IL-10 produced by peripheral APCs in the lymph nodes may be 
necessary for CD4+ T cells to differentiate to a neuroprotective subtype after axotomy. 
To confirm that a peripheral APC was not the necessary source of IL-10, FNA was 
performed on WT, IL-10-/-, and IL-10-/- mice reconstituted with WT whole splenocytes (a  
heterogeneous population of T cells, B cells, and APCs). FMN survival was determined 
at 28 dpo. In accordance with previously published findings (Xin et al., 2011), FMN 
survival in IL-10-/- mice (Figure 1A, 73.4 ± 2.77%) as well as in WT whole splenocyte-
reconstituted IL-10-/- mice (69.8 ± 3.11%) was significantly reduced compared to WT 
(84.4 ± 2.94%, p = 0.01), indicating that IL-10 produced by any peripheral immune 
source is not sufficient for FMN survival after axotomy.  
To confirm that transplanted WT splenocytes were able to successfully engraft 
into the IL-10-/- host, PCR was performed on genomic DNA extracted from WT, IL-10-/-, 
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and reconstituted IL-10-/- spleens using primers flanking a 133 bp sequence within exon 1 
of the IL10 gene. In the IL-10-/- animal, codons 5-55 of exon 1 are replaced with a 
termination codon followed by a neomycin cassette (Kuhn et al., 1993). Gel 
electrophoresis of the resulting PCR amplicons revealed that the 133 bp fragment was 
present in WT, absent in IL-10-/- mice, and restored in the IL-10-/- mice reconstituted with 
WT whole splenocytes, indicating that transplanted WT splenocytes were capable of 
engrafting into host lymphatic tissue and furthermore survived within the host until 28 
dpo (Figure 1B). 
 
4.1.2. IL-10/GFP reporter characterization1 
 With a peripheral immune contribution of neuroprotective IL-10 effectively ruled 
out, detection of the central source of IL-10 could proceed. A transgenic IL-10/GFP 
reporter mouse line was utilized to detect central sources of IL-10. This line was created 
by Dr. Christopher Karp’s laboratory via the insertion of an internal ribosome entry site 
(IRES) downstream of exon 5 of the Il10 locus (Madan et al., 2009). Transcription of the 
resultant IL-10/GFP fusion mRNA occurs under control of the endogenous IL-10 
promoter, but separate IL-10 and GFP proteins are translated. The result is independent, 
yet spatiotemporally coupled translation of IL-10 and GFP proteins, the former capable 
                                                 
 
1 The experiment contained within section 4.1.2 is reflective of a collaborative effort between Elizabeth 
Runge and Dr. Deborah Olmstead Setter. Data resulting from this experiment and presented here may 
overlap with those presented in Dr. Setter’s thesis (Setter, 2017) but are otherwise unpublished. Data to 
which this statement applies are presented here with permission from Dr. Setter. Future publication of these 
data will include Elizabeth Runge and Dr. Setter as co-authors. 
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of being secreted from the producing cell, and the latter remaining behind to label the cell 
body. 
 To confirm that the IL-10/GFP reporter represents a biological system capable of 
synthesizing and secreting functional IL-10 in a manner similar the WT animal, FNA was 
performed on WT and IL-10/GFP mice. Quantification of FMN survival at 28 dpo 
revealed no significant difference between WT and transgenic reporter (Figure 2, 83.5 ± 
3.24% and 79.83 ± 5.27% respectively, p = 0.57), indicating that IL-10 was functioning 
normally in the IL-10/GFP mice. 
 Determination of optimum conditions for detection of GFP in the IL-10/GFP 
reporter mouse revealed a detrimental effect of extensive PFA fixation on the ability to 
detect GFP signal (data not shown). It is possible that perfusion fixation denatured the 
GFP structure, which is a known issue when working with PFA (Kiernan, 2006). As both 
IL-10 and GFP expression in the reporter mouse are controlled by the endogenous IL-10 
promoter and thus are likely to be present at relatively low levels, the presence of 
aldehyde residue induced-autofluorescence may also obscure the GFP signal (Madan et 
al., 2009; Swenson et al., 2007). Therefore to preserve GFP labeling, brains were flash-
frozen immediately after removal, sectioned, and lightly post-fixed on the slide, thereby 
avoiding potential over-fixation due to perfusion-based methods. GFP was also amplified 




4.1.3. Central cellular localization of IL-102 
 Neurons, microglia, and astrocytes were investigated as potential sources of 
neuroprotective IL-10 in the axotomized FMNuc. It was hypothesized that microglia are 
the major central cellular source of IL-10, as it has been documented that microglia are 
capable of producing IL-10 in vitro (Ledeboer et al., 2002; Mizuno et al., 1994), 
particularly upon interacting with T cells (Chabot et al., 1999), as well in vivo in response 
to CNS injury (Ma et al., 2015). The cellular source of IL-10 was investigated in the 
FMNuc at 3, 7, 10, 14, and 28 days after axotomy. 
 
4.1.3.1. Neurons 
 The possibility of neuronal production of IL-10 was investigated utilizing IHC co-
labeling of GFP (as proxy for IL-10 production) with NeuN (neuronal nuclei marker) in 
the IL-10/GFP reporter mouse. NeuN is an RNA-binding protein involved in alternate 
mRNA splicing. It is associated with a mature neuronal phenotype; alteration of this 
phenotype in response to axotomy frequently results in diminished NeuN 
immunoreactivity, which is documented extensively in the literature (Darlot et al., 2017; 
Duan et al., 2016). This effect of axotomy on NeuN expression can be appreciated in 
Figure 3, particularly at 10 days post injury. NeuN labeling of axotomized FMN was 
nonetheless sufficient for detection. GFP labeling was detected in both the left and right 
                                                 
 
2 The IL-10/GFP reporter experiments contained within section 4.1.3 are reflective of a collaborative effort 
between Elizabeth Runge and Dr. Deborah Olmstead Setter. Data resulting from these experiments and 
presented here may overlap with those presented in Dr. Setter’s thesis (Setter, 2017) but are otherwise 
unpublished. Data to which this statement applies are presented here with permission from Dr. Setter. 
Future publication of these data will include Elizabeth Runge and Dr. Setter as co-authors. 
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FMNuc of the unoperated (sham) animal, as well as in the control and axotomized 
FMNuc of operated animals at all time points investigated (Figure 3). Across all 
conditions, GFP localized strongly to the cytoplasm of cells with NeuN-labeled nuclei. 
This GFP-neuronal co-localization did not change appreciably regardless of axotomized 




 A microglial source of IL-10 was next investigated utilizing the marker IBA1. 
IBA1 is specific to microglia in the CNS and is a commonly employed marker of 
microglial activation (Hoogland et al., 2015; Ito et al., 1998). It functions as an actin 
binding protein that is critical for microglial membrane ruffling and phagocytosis 
(Ohsawa et al., 2000; Sasaki et al., 2001). Although IBA1 reliably labels microglia in 
perfusion-fixed tissue, attempts to utilize the IBA1 marker in the flash-frozen IL-10/GFP 
reporter tissue failed to label microglia (data not shown). Antibody labeling for other 
microglia-associated markers, such as CD68 and F4/80, also failed to yield sufficient 
labeling of microglia, suggesting that microglial structures may be exquisitely sensitive to 
fixation methods. 
 As an alternate method of identifying IL-10 production by microglia, IBA1 
labeling was utilized alongside a direct antibody against IL-10 protein in WT tissue. This 
avoidance of the IL-10/GFP reporter permitted the use of perfusion fixation, which 
restored IBA1 labeling of microglia in the FMNuc (Figure 4). IL-10 antibody robustly 
labeled cells having a classic motoneuron morphology in both the control and axotomized 
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FMNuc at all time points. This IL-10 labeling appeared to be restricted to the cytoplasm 
and left a central clearing occupied by DAPI, which intercalates with DNA and labels 
cell nuclei. These data support the previous conclusion utilizing the IL-10/GFP reporter 
mouse that neurons are constitutive producers of IL-10 in the FMNuc. 
 IBA1 labeling in the control FMNuc revealed small numbers of microglia 
processes and the occasional resting microglia cell body (see Figure 4, 3 dpo C). After 
axotomy, increased IBA1 immunoreactivity was observed, with microglia appearing to 
ensheath injured motoneurons at 3, 7, and 10 dpo. This likely represents the movement of 
microglia into the perineuronal space after synaptic stripping of the FMN (Blinzinger & 
Kreutzberg, 1968; Torvik & Skjorten, 1971b). Microglia appeared in close proximity to 
the FMN and therefore also to FMN-associated IL-10 immunoreactivity, making 
discernment of neuronal- and microglial-associated expression of IL-10 difficult to 
distinguish. In some instances microglia appeared to co-localize with IL-10 signal (Figure 
4, arrowheads at 7 and 10 dpo), but upon close observation this apparent “co-
localization” was likely due to intimate association of microglia with neuronal processes. 
Most observed microglia appear not to co-localize with IL-10 labeling. At later time 
points (14 and 28 dpo), IBA1 labeled nodular structures which are likely clusters of 
microglia phagocytizing debris from dead neurons (Figure 4, arrows) (Raivich et al., 
1998; Torvik & Skjorten, 1971b). These clusters did not co-localize with IL-10 labeling. 
 Although IL-10 labeling of neurons appeared to be consistent between the IL-
10/GFP reporter and IHC on WT tissue, antibody labeling of a secreted ligand such as IL-
10 nonetheless presents a number of uncertainties. If a ligand is secreted rapidly, 
antibody may not label the cellular source; it is also possible that the antibody could label 
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the ligand bound to its extracellular receptor on another cell. Therefore, a second method 
of localization was desired to further elucidate whether microglia are a potential source of 
IL-10 in the FMNuc after axotomy. FISH was utilized to co-localize Il10 and Cx3cr1 
transcripts in the facial motor nucleus at 3 days post injury. Cx3cr1 encodes the 
fractalkine receptor, which is primarily expressed on microglia in the CNS and has 
important roles for intracellular calcium mobility and chemotaxis, particularly in 
response to neuronal damage (Harrison et al., 1998). FISH revealed the presence of 
scattered punctate areas of co-localized Il10 and Cx3cr1 probes in the control (left) 
FMNuc, which appeared to increase in number after axotomy (Figure 5). This raises the 
possibility that microglia make Il10 mRNA in the facial motor nucleus, but it is unknown 
whether this is translated into functional protein. 
 
4.1.3.3. Astrocytes 
 To determine whether astrocytes are a source of IL-10 in the facial motor nucleus, 
IHC labeling of the astrocyte-associated intermediate filament protein GFAP was 
utilized. Because it was found that reliable GFAP labeling can be achieved using both 
perfusion-fixed and lightly post-fixed flash frozen tissue, both the direct IHC method 
using IL-10 antibody on WT tissue as well as GFP labeling of IL-10/GFP reporter were 
utilized. Using direct IL-10 IHC, IL-10 again robustly labeled cells on both the control 
and axotomized FMNuc in a characteristic motoneuron-like pattern (Figure 6). GFAP 
labeling in the control FMNuc was mainly restricted to astrocytes lining penetrating 
blood vessels and along the glia limitans on the ventral edge of the brainstem. GFP co-
localized occasionally with GFAP-labeled astrocytes adjacent to blood vessels (Figure 6, 
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7 dpo C). GFAP-labeled astrocytes were detected within the FMNuc parenchyma in 
response to axotomy beginning at 3 dpo and persisting through 28 dpo. Weak IL-10 co-
localization with GFAP was detectable at early time points after axotomy (Figure 6, 
arrowheads at 3, 7, and 10 dpo) and increased in strength at later time points as GFAP-
labeled astrocytes became increasingly hypertrophied (arrowheads at 14 and 28 dpo). IL-
10 labeling appeared mainly in astrocyte cell bodies, but occasionally also labeled 
processes.  
IL-10/GFP reporter also displayed a progressive increase in GFAP 
immunoreactivity in the time points following axotomy, but unlike in the perfusion-fixed 
WT tissue, GFAP-labeled astrocytes were scarce at 3 dpo (Figure 6, right pane). This 
delay in the onset of GFAP immunolabeling is likely attributable to the fixation method 
used to preserve GFP signal in the reporter mouse. GFP labeling representing IL-10 
production began to co-localize with GFAP by 10 dpo. By 14 and 28 dpo, nearly all 
GFAP-labeled astrocytes observed in the FMNuc were also positive for GFP. GFP 
labeling other structures in the FMNuc, likely motoneurons, could be observed through 
all time points. 
In summary, axotomy induced expression of IL-10 by astrocytes. This expression 
was detectable beginning at early (3 dpo) time points when utilizing direct IL-10 
antibody in perfused tissue, and at later (10 dpo) time points using the IL-10/GFP 
reporter. This expression appeared to persist through 28 dpo using both labeling methods. 
Neuronal expression of IL-10 appeared to be constitutive and did not noticeably change 
after axotomy. Microglial production of IL-10 was not detected by immunohistochemical 
methods, although there is evidence that microglia may transcribe Il10 mRNA. 
 
56 
4.1.4. Cell-specific conditional IL-10 knockout3 
 With at least two potential sources of IL-10 in the FMNuc identified, it was next 
important to determine whether any single source was necessary for FMN survival after 
axotomy. Three mouse strains were created to selectively knock out IL-10 expression in 
single central cell populations using tamoxifen-inducible Cre recombination of floxed IL-
10 sequences. Cre recombinase expression was driven by the promoters for Thy1, 
Cx3cr1, and Gfap for targeted deletion of IL-10 in neurons, microglia, and astrocytes, 
respectively. The Thy1Cre mouse contains a modified Thy1 promoter region restricting its 
expression to neuronal cells (Caroni, 1997). Tamoxifen induction of Cre began one week 
prior to axotomy and continued until 28 dpo, at which time FMN survival was assessed. 
Littermates lacking either Cre or floxed IL-10 sequences were used as controls and 
received identical treatments to experimental mice.  
 Conditional knockout (cKO) of IL-10 did not significantly reduce FMN survival 
in any of the Cre-expressing mouse lines compared to littermate controls, indicating that 
IL-10 production by neurons, microglia, or astrocytes alone was not critical for 
neuroprotection after axotomy (Figure 7A, 85.7 ± 5.22% in control vs. 86 ± 6.27% in 
cKO, p = 0.97; 7B, 83.3 ± 3.65% vs. 88.1 ± 2.54%, p = 0.30; 7C, 81.3 ± 6.77%, vs 85.3 ± 
7.22%, p = 0.71, respectively). This is in agreement with the localization data showing 
IL-10 production by both neurons and astrocytes at minimum. It is likely that conditional 
                                                 
 
3 The CX3CR1Cre and GFAPCre experiments contained within section 4.1.4 are reflective of a collaborative 
effort between Elizabeth Runge and Dr. Deborah Olmstead Setter. Data resulting from these experiments 
and presented here may overlap with those presented in Dr. Setter’s thesis (Setter, 2017) but are otherwise 
unpublished. Data to which this statement applies are presented here with permission from Dr. Setter. 
Future publication of these data will include Elizabeth Runge and Dr. Setter as co-authors. 
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knockdown of IL-10 from one of these sources induces compensatory production by 
another. 
 
4.2. Aim 2: Characterize adaptive immune cell participation in neuroprotective IL-
10 receptor signaling after facial nerve axotomy 
4.2.1. Immunohistochemical identification of potential CD4+ T cell-neuron-glia 
interactions in the axotomized facial motor nucleus 
 It is unknown whether the CD4+ T cells responsible for mediating 
neuroprotection after axotomy are capable of infiltrating into the CNS parenchyma, or 
alternatively whether they must communicate with central cells across the blood-brain 
barrier. Immunohistochemical labeling was utilized to determine whether T cells are 
capable of entering the FMNuc after axotomy where they may potentially interact with 
centrally located cells. 
 
4.2.1.1. Detection of CD4+ T cells in FMNuc after axotomy 
 Utilization of an antibody against CD4 antigen revealed no infiltrate in the 
unoperated FMNuc (Figure 8A). In the contralateral axotomized FMNuc, small CD4+ 
cells appeared beginning at 10 dpo and persisting through 14 and 28 dpo (Figure 8B, 14 
dpo pictured). These cells were approximately 5–10 μm in diameter and consisted of a 
bright rim of CD4+ immunoreactivity surrounding a central DAPI-labeled nucleus in 
most sections. Many cells appeared elongated rather than perfectly circular in shape 
(Figure 8C). To ensure that these cells were true T cells as opposed to other CD4+ 
immune cells such as monocytes/macrophages, sections were also labeled with anti-CD3 
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antibody, which binds the T cell co-receptor. All CD4+ cells observed infiltrating the 
FMNuc were CD3+, but not all CD3+ T cells were CD4+, indicating that CD8+ T cells 
may also infiltrate the FMNuc after axotomy (Figure 8D–F). Collectively these data 
support findings in the literature indicating the presence of T cells in the FMNuc after 
axotomy (Bohatschek et al., 2004; Ha et al., 2007b; Ha et al., 2006; Huang et al., 2012; 
Raivich et al., 1998). 
 
4.2.1.2. Determination of CD4+ T cell infiltration into CNS parenchyma 
 Although CD4+ T cells were detected in the FMNuc after axotomy, this 
observation alone was not sufficient to determine whether they are capable of interacting 
directly with cells in CNS parenchyma, or whether they are restricted to the vascular 
compartment. In combination with anti-CD4 to label T cells and a fluorescent Nissl stain 
to label neurons, an antibody against CD31 was used to visualize vasculature in the 
FMNuc. CD31, also known as PECAM-1 (platelet/endothelial cell adhesion molecule 1), 
is enriched in cell-cell junctions in the vascular endothelium. This triple stain revealed the 
presence of small penetrating blood vessels in the control FMNuc without evidence of T 
cell infiltration (Figure 9A). CD4+ T cells were detectable in the axotomized FMNuc at 
14 dpo. These T cells appeared not to be contained within CD31-labeled blood vessels, 
indicating that they are capable of extravasating into the CNS parenchyma (Figure 9B–
D). Furthermore, some T cells appeared to be in close proximity to injured motoneurons 





4.2.1.3. Evaluation of CD4+ T cell association with microglia after axotomy 
CD4+ T cells must interact with MHCII on a central APC to mediate 
neuroprotection after axotomy (Byram et al., 2004). With the ability of CD4+ T cells to 
extravasate into the FMNuc parenchyma established, potential associations of CD4+ T 
cells with microglia, a prominent candidate for APC in the FMNuc, were next evaluated. 
Double labeling for CD4 and IBA1 revealed the presence of small resting microglia in 
the unaxotomized FMNuc that were not associated with any T cell infiltrate (Figure 
10A). At 14 dpo, microglia increased expression of IBA1, and a CD4+ T cell infiltrate 
into the injured FMNuc was observed (Figure 10B-D). These CD4+ T cells often 
appeared to be in close proximity with activated microglia and clustered around 
microglial nodules (Figure 10C-D). 
 In summary, IHC showed that CD4+ T cells infiltrate the FMNuc after axotomy. 
These T cells appear capable of crossing the blood-brain barrier and entering the CNS 
parenchyma where they may interact directly with central cells. Close associations of T 
cells with neurons and microglia in particular were observed. It is therefore possible that 
immune-mediated neuroprotection (as well as any other central molecular response to 
axotomy that is influenced by peripheral immune status) is effected by local paracrine 
signaling from infiltrating T cells or by direct contact between T cells and central cells in 
the FMNuc.  
 
4.2.2. Effect of immune status on central IL-10 receptor expression 
 To determine whether the adaptive immune system has an effect on central 
upregulation of the IL-10R after axotomy, qPCR was performed for IL-10R subunit gene 
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expression in the FMNuc at 7, 14, 28, and 56 dpo in WT and RAG-2-/- mice. Gene 
expression was calculated as percent increase in expression in the axotomized FMNuc 
relative to paired control FMNuc. Two-way ANOVA revealed that Il10ra expression was 
significantly different between WT and RAG-2-/-, although post hoc tests failed to detect 
a specific time point at which this effect was significant (Figure 11A, p = 0.0159). The 
percent increase in Il10rb expression was also significantly different between WT and 
RAG-2-/- (Figure 11B, p < 0.0001) ; RAG-2-/- mice had decreased Il10rb expression 
relative to WT particularly at 7 (114.2 ± 30.57% compared to 198.1 ± 16.86%, p = 
0.0019) and 14 dpo (100.7 ± 9.89% compared to 174.3 ± 15.18%, p = 0.0062). These 
data indicate that the adaptive arm of the immune system is necessary for full 
upregulation of IL-10R subunits in the FMNuc after axotomy. 
 To determine whether the CD4+ T cell specifically regulates IL-10R expression, 
the 14 dpo time point was selected for all subsequent analyses as this coincides with the 
peak of T cell infiltration into the FMNuc after FNA (Raivich et al., 1998) as well as the 
peak of microglial and astrocyte activation-associated gene expression (Setter et al., 
2018b). Gene expression was calculated as fold change of mRNA expression in 
axotomized FMNuc relative to control FMNuc. Fold change in Il10ra expression (Figure 
12A) was significantly reduced in RAG-2-/- (3.97 ± 0.26) compared to WT (5.70 ± 0.35, p 
< 0.05) and was restored to WT levels after adoptive transfer of WT CD4+ T cells (6.12 
± 0.38). Fold change in Il10rb expression (Figure 12B) was likewise significantly 
reduced in RAG-2-/- (2.06 ± 0.10) compared to WT (2.74 ± 0.15, p < 0.01), and adoptive 
transfer of WT CD4+ T cells restored normal Il10rb expression (2.74 ± 0.07).  
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This regulation of IL-10R expression by CD4+ T cells could be due to 1) T cell-
triggered induction of IL-10R expression on central cells, 2) infiltration of IL-10R-
expressing T cells into the FMNuc after axotomy, or 3) a combination of both 
mechanisms. To elucidate which scenario occurs after FNA, RAG-2-/- mice were 
reconstituted with CD4+ T cells lacking IL-10RB (Il10rb-/-), which is necessary for IL-10 
signal transduction (Kotenko et al., 1997; Spencer et al., 1998). Il10ra fold change in 
RAG-2-/- reconstituted with Il10rb-/- CD4+ T cells (Figure 12A, 7.54 ± 0.65) was 
significantly increased relative to RAG-2-/- (p < 0.001), indicating that IL-10 signaling 
within T cells was not necessary for T cells to regulate Il10ra gene expression in the 
FMNuc. In fact, upregulation of Il10ra in RAG-2-/- mice given Il10rb-/- CD4+ T cells was 
significantly greater than in WT or RAG-2-/- given WT CD4+ T cells (p < 0.05). Il10rb 
fold change in RAG-2-/- reconstituted with Il10rb-/- CD4+ T cells (Figure 12B, 2.64 ± 
0.09) was significantly increased relative to RAG-2-/- (p < 0.001) and was not 
significantly different from WT or RAG-2-/- + WT CD4+ T cells. Due to complete 
absence of Il10rb expression by the transgenic T cells, this restoration of Il10rb gene 
expression could only be due to a T cell-mediated induction of Il10rb in central cells in 
the FMNuc. Therefore it appears that CD4+ T cells mediate IL-10R expression on central 
cells in the FMNuc after axotomy regardless of their own IL-10R expression or function, 
although the presence and signaling capability of IL-10R on WT infiltrating T cells could 




4.2.3. Impact of IL-10 receptor-deficient CD4+ T cells on facial motoneuron survival 
after axotomy 
 Athough it was found that Il10rb-/- CD4+ T cells were capable of triggering an 
increase in IL-10R expression by central cells in the FMNuc, the neuroprotective 
capacity of these T cells remained unknown. It has previously been established that 
RAG-2-/- mice exhibit decreased FMN survival after axotomy relative to WT, and that 
WT CD4+ T cells restore FMN survival in RAG-2-/- mice to WT levels (Serpe et al., 
2003; Serpe et al., 2000). The ability of Il10rb-/- CD4+ T cells to mediate neuroprotection 
was assayed by counting FMN survival in WT, RAG-2-/-, and RAG-2-/- reconstituted with 
Il10rb-/- CD4+ T cells at 28 dpo. In accordance with the literature, survival in RAG-2-/- 
was significantly decreased compared to WT (Figure 13, 69 ± 1.3% compared to 81 ± 
3%, p <0.05). However, Il10rb-/- CD4+ T cells failed to rescue FMN survival; survival in 
reconstituted animals remained low compared to WT (61.8 ± 3.5%, p < 0.01).  
To confirm that adoptively transferred Il10rb-/- T cells were still viable in vivo at 
28 dpo, IHC was performed using spleens from WT, RAG-2-/-, and RAG-2-/- mice 
reconstituted with Il10rb-/- CD4+ T cells. WT spleens showed expression of CD3+/CD4+ 
T cells within follicles; CD3 labeling (specific for T cells) was lost in RAG-2-/- splenic 
follicles but was restored in RAG-2-/- given Il10rb-/- CD4+ T cells (Figure 14). 
Overall, these data suggest that the increase in IL-10R expression by central cells, 
although mediated by T cells, is insufficient for FMN survival after FNA; rather, IL-10R 




4.2.4. Central gene expression profile changes after facial nerve axotomy in mice 
reconstituted with wild-type or IL-10 receptor-deficient CD4+ T cells  
 IL-10R signaling in T cells is known to cause suppression of CD28 co-stimulation 
in the context of antigen presentation, resulting in T cell tolerance to antigen (Akdis et al., 
2000). Tolerized T cells can suppress the activation and proliferation of other T cells and 
inhibit APC expression of MHCII and co-stimulatory molecules in an antigen-specific 
manner (Chai et al., 1999; Vendetti et al., 2000). It is therefore likely that loss of IL-10R 
signaling in T cells permits them to become reactive against self-antigen. Once armed, 
effector T cells (particularly Th1 and Th17 cells) can activate APCs (including microglia) 
to a pro-inflammatory state (Chen et al., 2017; Dasgupta et al., 2002; Li et al., 2013; 
Murphy et al., 2010). Additionally, loss of tolerogenic T cells could disinhibit APC 
expression of MHCII and co-stimulatory molecules, thereby potentiating adaptive 
immune responses against self-antigen. 
 To investigate the role of T cell IL-10R signaling in modulating central APC 
activation after FNA, qPCR for genes associated with microglial/macrophage activation, 
antigen presentation, T cell co-stimulation, and complement deposition/synaptic pruning 
was performed in the FMNuc of WT, RAG-2-/-, and RAG-/- mice reconstituted with either 
WT CD4+ T cells (which confer neuroprotection after axotomy) or Il10rb-/- CD4+ T cells 
(which fail to confer neuroprotection). The hypothesis was that loss of IL-10 receptor 
signaling on T cells would promote a pro-inflammatory, autoimmune 




4.2.4.1. Genes associated with activated microglia: CD68, CD40, TNFα, TNF receptor, 
Nos2 
 After FNA, microglia proliferate in the FMNuc and express the pan-macrophage 
marker CD68 (Blinzinger & Kreutzberg, 1968; Graeber et al., 1988c; Torvik & Skjorten, 
1971b; Wainwright et al., 2010). At 14 dpo, Cd68 mRNA increased approximately six 
fold in the WT axotomized FMNuc; there was no difference in Cd68 expression between 
WT, RAG-2-/-, and RAG-2-/- mice reconstituted with WT CD4+ T cells (Figure 15A, 
6.078 ± 0.88, 5.809 ± 0.25, 6.785 ± 0.29, respectively). RAG-2-/- reconstituted with 
Il10rb-/- CD4+ T cells had significantly increased Cd68 expression (9.37 ± 0.69) relative 
to WT (p < 0.01), RAG-2-/-, and RAG-2-/- + WT CD4+ T cells (p < 0.05), indicating that 
Il10rb-/- T cells promote an increase in general microglial reactivity after axotomy. 
 CD40 is a co-stimulatory protein found on APCs that is necessary for their 
activation (Banchereau et al., 1994). At 14 dpo, Cd40 mRNA was modestly increased in 
the axotomized FMNuc relative to control across all conditions, and there were no 
significant differences between WT, RAG-2-/-, and RAG-2-/- + Il10rb-/- CD4+ T cells 
(Figure 15B, 1.57 ± 0.11, 1.46 ± 0.08, 2.17 ± 0.24, respectively). There was also no 
significant difference between RAG-2-/- reconstituted with WT CD4+ T cells (2.40 ± 
0.25) and those reconstituted with Il10rb-/- CD4+ T cells, although the former showed 
significantly increased Cd40 expression relative to WT and RAG-2-/- (p < 0.05). 
 TNFα is a pro-inflammatory cytokine secreted by classically activated microglia 
as part of the innate immune response to eliminate pathogens (Lull & Block, 2010). 
TNFα also acts on microglia in an autocrine fashion via ligation of TNF receptor 1 
(TNFR1, gene name Tnfrsf1) to promote further TNF- and other pro-inflammatory 
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cytokine-associated signaling (Kuno et al., 2005). No Tnf transcript was detected in the 
control FMNuc, in agreement with previous studies (Haulcomb et al., 2014; Setter et al., 
2018b). Therefore to compare changes in Tnf mRNA expression, the differences between 
Tnf and Gapdh cycle threshold values were normalized to a standardized spleen control, 
which was the same for each axotomized FMNuc sample. As shown in Figure 15C, Tnf 
mRNA in axotomized FMNuc at 14 dpo ranged between 1–3% of spleen standard, and 
no differences were observed between WT,  RAG-2-/-, RAG-2-/- + WT CD4+ T cells, and 
RAG-2-/- + Il10rb-/- CD4+ T cells (0.015 ± 0.003, 0.017 ± 0.004, 0.024 ± 0.005, 0.023 ± 
0.004, respectively). Tnfrsf1 mRNA approximately doubled relative to control FMNuc 
across all conditions; no significant differences were detected (Figure 15D, WT: 2.20 ± 
0.08, RAG-2-/-: 2.01 ± 0.13, RAG-2-/- + WT CD4: 2.11 ± 0.08, RAG-2-/- + Il10rb-/- CD4: 
2.10 ± 0.10). 
 Also upregulated in pro-inflammatory microglia, inducible nitric oxide synthase 
(iNOS, gene name Nos2) facilitates production of free radical nitric oxide (NO), which is 
cytotoxic to invading pathogens (Lull & Block, 2010; Moss & Bates, 2001). iNOS 
activity is also associated with neuroinflammation and neurodegenerative diseases such 
as MS (Dasgupta et al., 2002; Liu et al., 2002). At 14 dpo, Nos2 mRNA did not appear to 
be upregulated in the axotomized FMNuc and in fact maybe have been slightly decreased 
relative to control in WT and RAG-2-/- mice receiving Il10rb-/- CD4+ T cells (Figure 15E, 
results of one-sample t test against fold change of 1: WT, 0.76 ± 0.05, p = 0.008; RAG-2-
/- + Il10rb-/- CD4, 0.71± 0.09, p = 0.033). There were no significant differences detected 
between these groups and RAG-2-/- or RAG-2-/- mice receiving WT CD4+ T cells (0.87 ± 
0.17 and 0.78 ± 0.11, respectively). 
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 In summary, RAG-2-/- mice given Il10rb-/- CD4+ T cells showed increased 
expression of Cd68, indicating greater levels of microglial activation and/or proliferation. 
However, more specific markers alluding to a pro-inflammatory microglial phenotype 
were not significantly different between RAG-2-/- + Il10rb-/- CD4+ T cells and other 
conditions, indicating that the failure of Il10rb-/- CD4+ T cells to mediate neuroprotection 
is likely not due to their direct activation of microglia to an overtly cytotoxic state. 
 
4.2.4.2. Genes associated with antigen presentation and T cell co-stimulation: MHCII, 
CD80, and CD86 
 As innate immune cells and APCs of the CNS, microglia present antigen on 
MHCII to infiltrating CD4+ T cells (Yang et al., 2010). In order to become activated 
against antigen, T cells must also receive co-stimulatory signals from APCs via 
interactions of T cell CD28 antigen with APC CD80 and CD86 (also known as B7.1 and 
B7.2) (Janeway & Bottomly, 1994). However, this activation is not unidirectional; the 
interaction of T cells and microglia/macrophages also induces upregulation of microglial 
MHCII and co-stimulatory molecules to optimize their antigen-presenting capability, 
sustaining the adaptive immune response (Aloisi et al., 2000a; Yang et al., 2010). Both 
MHCII and CD86 are also upregulated on microglia in response to stimulation by 
classical activators such as IFNγ and LPS (Aloisi et al., 1998; Menendez Iglesias et al., 
1997; Satoh et al., 1995). 
  H2ab1 encodes the predominant MHCII haplotype expressed in C57BL/6J mice. 
Axotomy robustly induced H2ab1 in WT animals; expression increased approximately 
five fold relative to control FMNuc at 14 dpo (Figure 16A). RAG-2-/- mice that received 
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adoptive transfer of Il10rb-/- CD4+ T cells exhibited dramatically higher induction of 
H2ab1 expression after axotomy compared to WT, RAG-2-/-, and RAG-2-/- + WT CD4+ 
T cells (12.5 ± 1.88 vs. 4.9 ± 0.71, 6.1 ± 1.12, 5.8 ± 0.89, respectively; p < 0.01).  
Gene expression of the co-stimulatory molecule CD80 was modestly increased 
(approximate two-fold induction) in WT after axotomy; expression of Cd80 trended 
higher in RAG-2-/- + Il10rb-/- CD4+ T cells but was not significantly different from other 
conditions (Figure 16B, WT: 2.0 ± 0.28; RAG-2-/-: 1.3 ± 0.25; RAG-2-/- + WT CD4: 2.6 
± 0.56; RAG-2-/- + Il10rb-/- CD4: 3.2 ± 0.45). Expression of Cd86, however, increased 
much more robustly in response to axotomy, with approximate nine-fold induction in WT 
(Figure 16C). RAG-2-/- mice given Il10rb-/- CD4+ T cells exhibited significantly 
increased expression of Cd86 after axotomy compared to WT, RAG-2-/-, and RAG-2-/- + 
WT CD4+ T cells (13.7 ± 1.10 vs. 8.9 ± 0.67, 7.9 ± 1.13, 10.1 ± 1.24, respectively, p < 
0.05).  
Collectively these data show that loss of IL-10R signaling in T cells results in 
increased expression of genes encoding antigen presentation and T cell co-stimulatory 
molecules in the FMNuc after axotomy.  
 
4.2.4.3. Genes associated with synaptic pruning: B2m and C3 
 MHC class I is a cell surface molecule with complex roles in synaptic plasticity 
during development (Shatz, 2009), microglial phagocytic nodule formation (Bohatschek 
et al., 2004), and synaptic stripping after peripheral nerve injury (Oliveira et al., 2004; 
Sabha et al., 2008). Unlike MHCII, MHCI can be displayed on any nucleated cell in the 
body. B2m encodes the MHCI subunit β2-microglobulin. At 14 dpo, B2m expression 
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increased fivefold in the WT axotomized FMNuc and was not significantly different in 
RAG-2-/- mice (Figure 17A, 5.0 ± 0.28, 7.2 ± 0.85, respectively). Adoptive transfer of 
WT CD4+ T cells into RAG-2-/- resulted in significantly increased B2m expression 
relative to WT and RAG-2-/- (RAG-2-/- + WT CD4: 11.0 ± 1.02, vs WT, p < 0.001; vs. 
RAG-2-/-, p < 0.01). RAG-2-/- mice given Il10rb-/- CD4+ T cells had significantly 
increased expression of B2m after axotomy compared to WT, RAG-2-/-, and RAG-2-/- + 
WT CD4+ T cells (RAG-2-/- + Il10rb-/- CD4: 14.9 ± 0.81, vs. WT and RAG-2-/-, p < 
0.0001; vs. RAG-2-/- + WT CD4, p < 0.01). 
 The complement protein C3 is involved in microglial-mediated synaptic pruning 
(Schafer et al., 2012) as well as APC and T cell activation (Strainic et al., 2008). C3 
mRNA increased modestly in the FMNuc of WT mice after axotomy and was not 
significantly different in RAG-2-/- mice (Figure 17B, 2.6 ± 0.39, 0.9 ± 0.35, respectively). 
Adoptive transfer of WT CD4+ T cells into RAG-2-/- mice resulted in increased C3 
expression (5.3 ± 1.24, vs. WT, p < 0.05; vs. RAG-2-/-, p < 0.01). Adoptive transfer of 
Il10rb-/- CD4+ T cells resulted in even greater C3 expression than in WT, RAG-2-/-, or 
RAG-2-/- + WT CD4+ T cells (9.4 ± 0.86, vs. WT and RAG-2-/-, p < 0.0001; vs. RAG-2-/- 
+ WT CD4, p < 0.01). 
 In summary, adoptive transfer of Il10rb-/- CD4+ T cells increased central 
expression of genes associated with microglial activation (Cd68), antigen presentation 
(H2ab1 and B2m), T cell co-stimulation (Cd86), and synaptic pruning (B2m and C3) after 
axotomy, without increasing markers that would indicate an overtly pro-inflammatory 
microglial phenotype (Cd40, Tnf, Tnfrsf1, Nos2). These data suggest that loss of IL-10R 
signaling in T cells results in enhancement of antigen presentation by central APC 
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(probably microglia), which may facilitate ongoing adaptive immune activation against 




Figure 1: FMN survival in WT, IL-10-/-, and IL-10-/- mice reconstituted with WT whole 
splenocytes and splenocyte engraftment confirmation. 
 
A) Average percent survival of axotomized FMN relative to control ± SEM at 28 dpo. No 
significant difference was detected between IL-10-/- and IL-10-/- receiving splenocytes; 
survival in both groups was significantly decreased relative to WT (* p < 0.05). B) PCR 
amplicon gel showing a 133 bp fragment (arrow) of exon 1 of the IL10 coding sequence 
which is present in WT, absent in IL-10-/-, and restored in IL-10-/- reconstituted with WT 




Figure 2: FMN survival in WT and IL-10/GFP reporter mice. 
 
Average percent survival of axotomized FMN relative to control ± SEM at 28 dpo. No 
significant difference was detected between WT and reporter.  
 
E. M. Runge and D. O. Setter (Setter, 2017) contributed equally to this figure. 









Figure 3: IHC co-localization of neurons (NeuN) with GFP in IL-10/GFP reporter mouse. 
 
Dpo = days post operation, C = control (left) FMNuc, Ax = axotomized (right) FMNuc. 
 
E. M. Runge and D. O. Setter (Setter, 2017) contributed equally to this figure. Data 








Figure 4: Direct IHC localization of microglia (IBA1) and IL-10 in WT mice. 
 
Arrowheads at 7 and 10 dpo demonstrate microglia lying in close proximity to IL-10-
positive neuronal processes. Arrows at 14 and 28 dpo indicate microglial nodules.  
 










Figure 6: IHC co-localization of astrocytes (GFAP) with IL-10 using both direct IL-10 
antibody and IL-10/GFP reporter.  
 
Left panels depict direct IL-10 antibody, right panels depict reporter. Arrowheads 
indicate areas of co-localization.  
 
Dpo = days post operation, C = control (left) FMNuc, Ax = axotomized (right) FMNuc. 
 
E. M. Runge and D. O. Setter (Setter, 2017) contributed equally to the IL-10/GFP 





Figure 7: FMN survival in IL-10 cKO mice compared to littermate controls. 
 
Average percent survival of axotomized FMN relative to control ± SEM at 28 dpo in 
mice lacking IL-10 in A) neurons, B) microglia, and C) astrocytes. No significant 
differences were seen between littermates and cKO. 
 
E. M. Runge and D. O. Setter (Setter, 2017) contributed equally to panels B and C in this 








Figure 8: IHC identification of CD4+ T cells in the FMNuc. 
 
A)  20X image of control FMNuc at 14 dpo with no CD4+ cells. B) 20X image of axotomized FMNuc at 14 dpo with CD4+ cell 
infiltration. C) 40X image of box in B. D) 20X composite image of axotomized FMNuc at 14 dpo with CD4+ cells. White dashed line 
indicates boundary of FMNuc. E) Same field as D showing CD3+ cells. F) Overlaid channels in D and E showing CD3+/CD4- and 
CD3+/CD4+ T cells. Scale bar in A = 100 μm and applies to A and B. Scale bar in C = 50 μm. Scale bar in D = 100 μm and applies to 




Figure 9: IHC of CD4+ T cells and CD31-labeled endothelial layer of blood vessels 
penetrating the FMNuc. 
 
A) 20X composite image of control FMNuc at 14 dpo showing no infiltrating T cells. B) 
20X composite image of axotomized FMNuc at 14 dpo. C,D) 40X magnified fields from 
boxes in B showing CD4+ T cells not contained within CD31-labeled blood vessels. Note 
CD4+ T cells marked with arrowheads in close proximity to FMN labeled with 
fluorescent Nissl stain. Scale bar in A = 100 μm and applies to A and B. Scale bar in C = 





Figure 10: IHC of CD4+ T cells and IBA+ microglia in the FMNuc. 
 
A) 20X composite image of control FMNuc at 14 dpo. Small resting microglia can be 
observed. B) 20X composite image of axotomized FMNuc at 14 dpo with infiltrating 
CD4+ T cells and microglial activation indicated by increased IBA1 immunoreactivity. 
C,D) Magnified fields showing close association of CD4+ T cells and microglia. Note 
cluster of microglia and T cells in nodule-like structure. Scale bar in A = 100 μm and 





Figure 11: Effect of immune status on central IL-10 receptor expression. 
 
mRNA percent increase in expression of genes in the axotomized FMNuc relative to 
control FMNuc. Bars represent mean percent change ± SEM. For Il10ra, two-way 
ANOVA revealed a significant overall difference between WT and RAG-2-/-, but post-
hoc tests failed to determine at which specific time points differences existed.  * p < 0.05, 





Figure 12: Expression of IL-10R subunit genes at 14 days post FNA in WT, RAG-2-/-, 
RAG-2-/- + WT CD4+ T cells, and RAG-2-/-+ Il10rb-/- CD4+ T cells. 
 
mRNA fold change of genes in the axotomized FMNuc relative to control FMNuc. Bars 





Figure 13: FMN survival in WT, RAG-2-/-, and RAG-2-/- reconstituted with Il10rb-/- 
CD4+ T cells. 
 
Average percent survival of axotomized FMN relative to control ± SEM at 28 dpo. 
Survival in both RAG-2-/- and RAG-/- reconstituted with CD4+ T cells was decreased 
relative to WT, indicating that Il10rb-/- T cells fail to confer neuroprotection. * p < 0.05, 





Figure 14: Confirmation of IL10RB-/- CD4+ T cell engraftment at 28 dpo. 
 
In WT animals, splenic follicles are CD3+/CD4+. In RAG-2-/-, splenic follicles are 
negative for CD3+ T cells. Adoptive transfer of Il10rb-/- CD4+ T cells restores CD3+ 
expression in splenic follicles, indicating that Il10rb-/- CD4+ T cells are were successfully 







Figure 15: Expression of genes association with microglial activation at 14 days post 
FNA in WT, RAG-2-/-, RAG-2-/- + WT CD4+ T cells, and RAG-2-/- + Il10rb-/- CD4+ T 
cells. 
 
mRNA fold change of genes in the axotomized FMNuc relative to control FMNuc 
(except for C, which reflects relative expression in axotomized FMNuc relative to spleen 




Figure 16: Expression of genes association with antigen presentation and T cell co-
stimulation at 14 days post FNA in WT, RAG-2-/-, RAG-2-/- + WT CD4+ T cells, and 
RAG-2-/-+ Il10rb-/- CD4+ T cells. 
 
mRNA fold change of genes in the axotomized FMNuc relative to control FMNuc. Bars 





Figure 17: Expression of genes associated with synaptic pruning at 14 days post FNA in 
WT, RAG-2-/-, RAG-2-/- + WT CD4+ T cells, and RAG-2-/-+ Il10rb-/- CD4+ T cells. 
 
mRNA fold change of genes in the axotomized FMNuc relative to control FMNuc. Bars 
represent mean fold change ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001,  




CHAPTER 5: DISCUSSION 
5.1. Aim 1 Discussion 
 The goal of this aim was to determine the central cellular sources of IL-10 in the 
FMNuc and the respective contributions of these sources to FMN survival after axotomy. 
The anti-inflammatory cytokine IL-10 was first discovered as a Th2-secreted factor that 
suppresses IFNγ production by activated Th1 cells (Fiorentino et al., 1989). IL-10 has 
since been recognized as a major immunoregulator with roles in T cell development, 
macrophage and dendritic cell activation, and antigen presentation (Fiorentino et al., 
1991a; Kuhn et al., 1993; MacNeil et al., 1990; Steinbrink et al., 1997). IL-10 is also 
important for the resolution of inflammation after CNS injury and disease, an effect 
which is frequently mediated by IL-10-producing CD4+ T cells and microglia (Frenkel et 
al., 2005; Gravel et al., 2016; Mayo et al., 2016; Park et al., 2007; Zhou et al., 2017).  
CD4+ T cells are critical for WT levels of FMN survival after FNA (Serpe et al., 
2003). IL-10 is necessary for CD4+ T cells to mediate neuroprotection after axotomy, but 
surprisingly, CD4+ T cells are not the source of IL-10 in this injury model (Xin et al., 
2011). IL-10 is incapable of crossing the blood-brain barrier; because FNA does not 
cause mechanical damage to the blood-brain barrier, it is most likely that the IL-10 
important for neuroprotection derives from a central source in the facial motor nucleus 
(Kastin et al., 2003; Raivich et al., 1998). However, it is also possible that IL-10 
production by a peripheral APC is important for the differentiation of neuroprotective 
Th2 cells. Therefore, it was first necessary to rule out an IL-10 contribution from the 
peripheral immune system (see discussion section 5.1.1).  
In the CNS, microglia are the most likely producers of IL-10 after axotomy. 
Microglia are capable of IL-10 production following IFNγ and LPS challenge in vitro and 
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in vivo (Ledeboer et al., 2002; Mizuno et al., 1994; Park et al., 2007; Williams et al., 
1996). The expression of pro- and anti-inflammatory markers by microglia in vitro 
enables crude categorization of microglia into “M1” and “M2” subtypes, although 
microglial polarization in vivo exists along a more nuanced spectrum (Martinez & 
Gordon, 2014). IL-4 induces the polarization of M2-type microglia, which produce IL-10 
and are characterized by decreased expression of inflammatory mediators such as NO and 
co-stimulatory molecules such as CD86 (Chhor et al., 2013; Zhang et al., 2014). IL-4 is 
the signature cytokine of the Th2 cell subset critical for neuroprotection after axotomy, 
and microglia produce more IL-10 after interacting with T cells in vitro (Chabot et al., 
1999; Deboy et al., 2006b). After spinal cord injury, M2-type macrophages can also 
reciprocally promote neuroprotective Th2-predominant immune responses (Ma et al., 
2015). In light of this evidence, it was hypothesized that IL-4-producing Th2 cells travel 
into the FMNuc after axotomy, where they promote microglial production of IL-10 that is 
necessary for neuroprotection.  
 
5.1.1. The contribution of IL-10 from the peripheral immune system is not sufficient for 
motoneuron survival after axotomy 
Although IL-10 production by CD4+ T cells was effectively excluded as being 
necessary for neuroprotection after axotomy (Xin et al., 2011), IL-10 production by other 
peripheral immune cells, such as dendritic cells or macrophages, remained a potential 
neuroprotective alternative given the ability of peripheral IL-10 to modulate T cell subset 
activation. After facial nerve axotomy, most CD4+ T cell subsets–including Th1, Th2, 
Th17, Tr1, and FOXP3+ Tregs–expand in the draining lymph nodes (Xin et al., 2008). 
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However, only the IL-4-producing Th2 subset in particular mediates neuroprotection 
(DeBoy et al., 2006a; Deboy et al., 2006b). IL-10 suppresses APC-induced IFNγ 
secretion by Th1 cells, but largely does not affect IL-4 production by Th2 cells 
(Fiorentino et al., 1989; Fiorentino et al., 1991b). IL-10 suppresses Th1 function 
primarily by decreasing MHCII and co-stimulatory molecule expression on APCs (de 
Waal Malefyt et al., 1991; Ding et al., 1993; Ding & Shevach, 1992). There is also 
evidence that IL-10 can prime dendritic cells to skew the differentiation of naïve T cells 
toward the Th2 subset, which is supported by studies indicating that IL-10-/- mice have 
Th1-predominant immune responses (Berg et al., 1996; Liu et al., 1998). The 
predominance of pro-inflammatory Th1/Th17 responses over anti-inflammatory 
Treg/Th2 responses is characteristic of several neurodegenerative diseases, including 
ALS and MS (Mantovani et al., 2009; Rentzos et al., 2012; Saresella et al., 2013).  
 IL-10 produced by APCs in the periphery could set up conditions ideal for Th2 
subset differentiation and function, which would have implications for overall adaptive 
immune neuroprotective capacity after axotomy. To rule out IL-10 from a peripheral 
APC as being necessary for central neuroprotection after FNA, IL-10-/- mice were 
adoptively transferred with WT whole splenocytes. The whole splenocyte milieu includes 
innate (granulocytes, monocytes/macrophages, and dendritic cells), adaptive (T and B 
cells), and stromal cells. After adoptive transfer, only cells in the peripheral immune 
compartment express the WT IL-10 gene. The observed failure of whole splenocytes to 
rescue FMN survival indicates that IL-10 from any peripheral immune cell, including 
APCs, is not sufficient for neuroprotection after axotomy. This result reinforces the 
hypothesis that a central source of IL-10 is critical for FMN survival. 
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It has been previously demonstrated that adoptive transfer of whole splenocytes 
into RAG-2-/- mice results in restoration of normal splenic architecture, indicating 
successful engraftment of transplanted cells into host tissue (Serpe et al., 1999). 
However, it was unknown whether the intact (and hyper-reactive) peripheral immune 
system of the IL-10-/- mouse would permit adoptive transfer of foreign splenocytes. 
Failure of transplanted immune cells to rescue FMN survival could simply indicate 
immune rejection. PCR amplification of genomic DNA revealed the presence of the WT 
IL-10 gene in the spleens of IL-10-/- animals that had received WT splenocytes, 
indicating that these cells survived in the IL-10-/- spleen up to four weeks after axotomy. 
Although IL-10 production by peripheral immune cells appears not to be 
sufficient for FMN survival after axotomy, a peripheral immune source of IL-10 does 
have a role in axon regeneration in the periphery. IL-10-expressing macrophages 
infiltrate the sciatic nerve after crush injury and appear to be important for resolution of 
the pro-inflammatory phase of Wallerian degeneration, which is important for clearance 
of tissue debris (Sawada et al., 2007; Siqueira Mietto et al., 2015). IL-10-/- mice have 
slower axon regeneration and delayed recovery of sensory and motor function after 
sciatic crush (Siqueira Mietto et al., 2015). Exogenous application of IL-10 after sciatic 
nerve transection and suture reduces collagen deposition and improves transduction of 
compound action potentials across the injury site (Atkins et al., 2007). These data suggest 
dual location-dependent roles for IL-10 after axotomy, both of which are essential for 
functional recovery: central IL-10 is critical for FMN survival, whereas peripheral IL-10 
from immune sources is important for axon regrowth. 
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5.1.2. Facial motoneurons constitutively express IL-10, and this expression is not affected 
by axotomy 
 Use of an IL-10/GFP reporter mouse revealed GFP co-localization with NeuN-
labeled neurons in both the control and injured FMNuc of animals that received axotomy, 
as well as in un-operated sham control animals. Supporting these results, an antibody 
specific for IL-10 labeled the cytoplasm of cells in the FMNuc having a distinct 
motoneuron morphology (large, multipolar cells with prominent central nuclear 
clearings). This labeling was also present in both control and axotomized FMNuc and did 
not appreciably change in response to axotomy. These results were unexpected, given the 
relative dearth of studies in the literature showing IL-10 production by neurons compared 
to glia. One report on IL-10 expression in the context of cerebral ischemia showed strong 
co-localization of both IL-10 and its receptor with healthy cortical, striatal, and 
hippocampal neurons (Fouda et al., 2013). In postmortem spinal cord samples, IL-10 co-
localizes with neurons in both control and ALS patients, but in the latter appears to be 
restricted to intracellular TDP-43 inclusions, suggesting that neurons make IL-10 that can 
become sequestered in disease (Berjaoui et al., 2015).  
 In vitro studies of primary neuron cultures reveal insights both into the possibility 
of neuronal production of IL-10 as well as potential reasons for its constitutive 
expression. Low basal production of IL-10 that increased after prolonged toll-like 
receptor (TLR) stimulation was observed in one study of primary neurons cultured in 
serum-free media (Chistyakov et al., 2018). Another found that application of an IL-10 
neutralizing antibody in the absence of exogenous IL-10 or serum-containing media 
suppressed JAK1/STAT3 activation, increased apoptosis, decreased neurite extension by 
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suppressing Netrin-1 signaling, suppressed synaptophysin expression, and reduced the 
density of dendritic spines in primary neuron cultures subjected to oxygen-glucose 
deprivation (Chen et al., 2016). These data suggest that endogenous IL-10 production by 
neurons may have an autocrine role in conferring resistance to ischemia and metabolic 
stress and potentially is important for maintenance of synapses. However, conclusions 
drawn from studies of primary neuron cultures must be conservative, as glial 
contamination of cultures is a possibility. An autocrine role for neuronal IL-10 is 
supported in vivo by reports that FMN and healthy cortical neurons also express the IL-
10R constitutively (Fouda et al., 2013; Villacampa et al., 2015; Xin et al., 2011). 
 
5.1.3. Astrocyte production of IL-10 is induced by axotomy 
 Both IL-10/GFP reporter and direct IL-10 immunohistochemistry revealed 
induction of GFAP-labeled astrocyte expression that co-localized with IL-10 production 
in the axotomized FMNuc. Using the direct labeling method, co-localization of astrocytes 
with IL-10 occurred as early as 3 dpo and persisted through 28 dpo. IL-10/GFP reporter 
exhibited a delayed astrocyte response compared to direct IL-10 IHC, with prominent 
GFAP expression not observed until 7 dpo and GFP co-localization delayed until 10 dpo. 
This difference is likely due to more thorough fixation of proteins in the WT mouse 
tissue used for direct IL-10 IHC.  WT tissue was perfusion-fixed prior to sectioning, 
whereas IL-10/GFP reporter mouse tissue was flash-frozen, sectioned, and fixed on the 
slide in order to preserve GFP signal.  
 Astrocyte production of IL-10 has been characterized both in vitro and in vivo. 
Reports of IL-10 production by resting or unstimulated astrocytes are conflicted. Some 
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studies indicate that IL-10 mRNA and protein expression is negligible in unstimulated 
primary cultured astrocytes (Wirjatijasa et al., 2002), especially in comparison with 
microglia (Ledeboer et al., 2002). Others report low constitutive production of IL-10 by 
primary astrocytes in plain culture media (Chistyakov et al., 2018) and greater production 
when exposed to cerebrospinal fluid (CSF) in the absence of additional stimulation 
(Mishra et al., 2016). Regardless of their constitutive expression of IL-10, cultured 
primary astrocytes are known increase expression of both IL-10 mRNA and protein in 
response to LPS and TLR stimulation in a dose-dependent fashion (Chistyakov et al., 
2018; Ledeboer et al., 2002; Mizuno et al., 1994). It is also noteworthy that the fold-
change in astrocyte production of IL-10 is greater than that in microglia in glial co-
cultures, suggesting that astrocytes are more sensitive to stimuli that trigger IL-10 
production (Ledeboer et al., 2002). Interestingly, IL-10 production by astrocytes is 
suppressed when they are exposed to CSF from patients with ALS, suggesting the 
presence of a pro-inflammatory factor that shuts down normal IL-10 secretion (Mishra et 
al., 2016). 
 In vivo, astrocyte production of IL-10 has been documented in both human 
patients with MS and rodent models of experimental autoimmune encephalomyelitis 
(EAE). In human postmortem brain tissue samples, IL-10, IL-4, and their receptors co-
localize with reactive astrocytes in active demyelinating MS lesions as well as in areas of 
brain infarction (Hulshof et al., 2002). Another study in human MS tissue detected 
prominent co-labeling of IL-10 and astrocytes around blood vessels adjacent to acute 
lesions and in the hypercellular rim of chronic active lesions (Cannella & Raine, 1995). 
These locations suggest a role for astrocytic IL-10 in restricting the area of inflammatory 
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cell infiltration. IL-10 mRNA and protein also co-localize with perivascular astrocytes 
that lie in close proximity to peripheral immune infiltrates in EAE. Interesting, microglia 
as well as infiltrating macrophages and T cells also express IL-10 in this model (Jander et 
al., 1998). These perivascular astrocytes form glial-scar-like barriers that restrict 
inflammatory adaptive immune cell infiltration (Voskuhl et al., 2009). 
 Targeted overexpression of IL-10 by astrocytes also modifies the cellular 
responses to FNA. This increase in astrocytic IL-10 induces greater upregulation of IL-
10R expression on FMN, suggesting a feed-forward role of IL-10 in the FMNuc that 
promotes its own signaling (Villacampa et al., 2015). These data support findings from 
our laboratory showing that while total IL-10 protein levels do not significantly change in 
the FMNuc after axotomy, there is increased IL-10R expression and therefore likely 
increased IL-10 signaling events overall (Xin et al., 2011). The adaptive immune system 
is also essential for full upregulation of IL-10R expression in the FMNuc after axotomy 
(Aim 2 of this study). In the aforementioned study, greater production of astrocyte IL-10 
is paradoxically associated with increased microglial nodule formation and MHCII 
expression as well as a two-fold increase in CD3+ T cell infiltration into the FMNuc. 
FMN survival is also improved in this model, however, the authors report much lower 
FMN survival in WT mice than what is typically observed in our laboratory (65% at 21 
dpo vs. 85% at 28 dpo in our laboratory), and survival in their IL-10-overexpressing 
animals (81%) was comparable to what we typically observe in WT animals (Villacampa 
et al., 2015). 
 Altogether, these data indicate roles for astrocyte production of IL-10 in 
modulating the immune response to injury or disease as well as promoting 
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neuroprotective IL-10 signaling in neurons. This immune modulation may take the form 
of an immunosuppressive role, as is seen in MS (Cannella & Raine, 1995; Hulshof et al., 
2002), or it potentially may favor the infiltration of neuroprotective T cell subsets, as is 
implied by Villacampa et al. (2015). As previously described, overall IL-10 protein levels 
do not significantly change in the FMNuc after axotomy (Xin et al., 2011); therefore, the 
amount of IL-10 produced by astrocytes may be small in comparison with that produced 
constitutively by neurons, or perhaps there is a slight decrease in IL-10 production by 
neurons after axotomy that is undetectable by IHC and compensated for by astrocytes. As 
astrocytes are both highly mobile and frequently optimally situated for surveillance of the 
blood-brain barrier, a shift in IL-10 production toward the astrocyte suggests a more 
immunomodulatory role after axotomy in comparison with constitutive IL-10 expression 
in neurons. 
 
5.1.4. Microglia appear not to produce IL-10 protein after facial nerve axotomy 
 The IL-10/GFP reporter mouse could not be utilized for co-labeling of microglia 
as all microglial antigens tested were undetectable by antibody labeling in the flash-
frozen tissue. Use of perfusion-fixed tissue enabled excellent detection of IBA1 positive 
microglia after axotomy. At early time points after axotomy, microglia could be observed 
ensheathing injured FMN, while at later time points they formed phagocytic nodules. At 
no point was definite co-labeling of IBA1 and IL-10 detected, suggesting that microglia 
do not make IL-10 after axotomy. Microglial production of IL-10 after axotomy therefore 
remains somewhat ambiguous, as the IL-10 antibody may not bind IL-10 within its 
cellular source if it is rapidly secreted after synthesis. The particular antibody utilized in 
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this study neutralizes IL-10 and prevents it from binding to its receptor, indicating that it 
should only label free or intracellular IL-10 and not IL-10 bound to its receptor a target 
cell (Xie et al., 2015). Other studies have been published utilizing antibody detection of 
IL-10 with successful labeling of microglia and macrophages/monocytes (Hulshof et al., 
2002; Jander et al., 1998; Park et al., 2007; Siqueira Mietto et al., 2015), but it is likely 
that the dynamics of IL-10 production by microglia differs in different injury and disease 
models. Despite this finding, Il10 mRNA co-localized with Cx3cr1 mRNA both in the 
control and axotomized FMNuc. It has been reported that production of IL-10 is heavily 
regulated on a post-transcriptional level, as many cell types express Il10 mRNA 
constitutively but do not translate IL-10 protein (Powell et al., 2000; Tone et al., 2000). 
This may represent a mechanism by which microglia can rapidly synthesize IL-10 only 
after the correct stimulus. 
 IL-10 production by microglia in culture is similar to what is seen in peripheral 
macrophages. Some reports indicate constitutive production of microglia in primary 
culture (Ledeboer et al., 2002), while others report trace or negligible production (Chabot 
et al., 1999; Hulshof et al., 2002; Mizuno et al., 1994). LPS stimulation triggers increased 
IL-10 mRNA and protein production by microglia in a dose-dependent manner (Ledeboer 
et al., 2002; Mizuno et al., 1994). Microglia derived from presymptomatic ALS mice 
produce more IL-10 in response to LPS challenge, suggesting a compensatory response 
to ongoing neuroinflammation (Gravel et al., 2016). TLR stimulation (Jack et al., 2005) 
and purinergic receptor activation (Seo et al., 2008) also stimulate IL-10 production by 
microglia in vitro.  Microglial production of IL-10 is dramatically increased when co-
cultured with T cells, a phenomenon which is reversible via CD40 and CD80/86 blockade 
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(Chabot et al., 1999); along similar lines, IFNγ (produced by Th1 cells and a potent 
activator of macrophages) also promotes IL-10 production by microglia in vitro 
(Williams et al., 1996).  
In vivo demonstrations of microglial IL-10 production are somewhat scarcer. LPS 
injection stimulates microglial production of IL-10 in vivo; interestingly, these microglia 
are also immunopositive for IL-1β, TNFα, and iNOS, suggesting a microglial phenotype 
that is not strictly pro- nor anti-inflammatory. Blockade of IL-10 signaling causes a 
significant increase in neuron cell death in the cerebral cortex after LPS injection (Park et 
al., 2007). IL-10 production by spinal cord parenchymal microglia is seen in rodent 
models of EAE (Jander et al., 1998) as well as in active MS lesions in humans (Hulshof 
et al., 2002), although the effect is not as robust as what is observed in astrocytes. In an 
ALS mouse model, targeting IL-10 overexpression to microglia results in delayed disease 
onset and a modest increase in survival (Gravel et al., 2016). 
Altogether, these data suggest that while microglia are capable of producing IL-10 
in response to overt inflammatory stimuli in vitro and in vivo, the relatively mild 
inflammation induced by FNA may not severe enough to trigger IL-10 production to a 
degree that is detectable by IHC. Alternate methods of detection, such as flow cytometry, 
may be better suited to detecting subtle changes in microglial IL-10 synthesis if 




5.1.5. No single central source of IL-10 in the facial motor nucleus is critical for 
neuroprotection 
 To determine whether IL-10 production by neurons, astrocytes, or microglia is 
necessary for CD4+ T cell-mediated neuroprotection, a Cre/Lox system was employed to 
selectively knock out IL-10 production in each of these populations prior to axotomy. 
Selective deletion of IL-10 revealed that production by any of these single central sources 
was not critical for neuroprotection. These data are in accordance with previous findings 
that IL-10 is produced by at least two cell populations in the FMNuc (neurons and 
astrocytes), with microglial production of IL-10 ambiguous after axotomy. After 
knockout, it is likely that the IL-10 remaining from one source is sufficient to mediate 
neuroprotection on its own; similarly, selectively knocking out IL-10 production from a 
single source may induce enhanced compensatory production from another.  
 Compensation of a cytokine after knockout by an alternative source is a common 
phenomenon. For example, IL-17 is typically produced by Th17 cells in a renal ischemia-
reperfusion model, but can also be produced by natural killer cells when the model is 
imposed on a T cell-deficient background (Mehrotra et al., 2017). Compensation of 
cytokine knockout by an alternative redundant cytokine is also frequently observed in the 
literature (Khader et al., 2005; McMahon et al., 2001; Nedvetzki et al., 2004), although 
such redundancy is unlikely to be occurring in our model as IL-10-/- mice have reduced 
FMN survival (Xin et al., 2011). It is likely that both neuronal and astrocyte production 
of IL-10 in tandem is necessary for FMN survival after axotomy, and future studies will 




5.1.6. Summary of results and revised hypothesis 
 These data demonstrate that IL-10 from a peripheral immune source is 
insufficient to support FMN survival after axotomy, indicating that a central source of IL-
10 is critical for neuroprotection. IL-10 is produced constitutively by motoneurons in the 
FMNuc and is induced in astrocytes after axotomy. Microglia may constitutively 
transcribe Il10 mRNA, but there is currently no evidence for translation of IL-10 protein 
in microglia after FNA. Neuroprotective IL-10 does not derive exclusively from neurons, 
astrocytes, or microglia. From these data, a revised hypothesis of IL-10 action in the 
FMNuc after FNA is that neuronal production of IL-10 serves a homeostatic role for 
neuron resilience to stress by supporting neuron survival and synaptogenesis in an 
autocrine fashion. IL-10 produced by astrocytes after FNA, in addition to exerting trophic 
influences on neurons, may also modulate the infiltrating immune milieu in a 
neuroprotective manner. A trophic role for IL-10 is supported by data indicating that 
there is constitutive neuronal expression of the IL-10R in the FMNuc which changes after 
axotomy, especially in response to IL-10 produced by astrocytes (Villacampa et al., 2015; 
Xin et al., 2011; see section 5.2.2 for further discussion). The importance of peripheral 
immune responsiveness to IL-10 signaling after axotomy is crucial to elucidate and is 
addressed by Aim 2 of this study. 
 
5.1.7. Limitations of this study and future directions 
 Although this study thoroughly investigates expression of IL-10 by neurons, 
astrocytes, and microglia in the FMNuc, other central cell types have gone relatively 
unexplored. Oligodendrocytes, ependymal cells, pericytes, and perivascular macrophages 
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are also candidates for IL-10 production after axotomy. Perivascular macrophages in 
particular may produce IL-10 in the context of MS (Hulshof et al., 2002). Perivascular 
macrophages in the FMNuc also upregulate MHCII after axotomy, raising the possibility 
of interactions with CD4+ T cells at the blood-brain barrier that could potentially be 
vulnerable to IL-10 modulation (Villacampa et al., 2015). These cells are likely not 
replenished by circulating monocytes and thus would evade influence by the adoptive 
whole splenocyte transfer performed in this study (Faraco et al., 2017).  
 In the periphery, SCs and endoneurial cells are alternative sources of IL-10 that 
would also not be reconstituted by WT whole splenocyte transfer into the IL-10-/- animal. 
Sciatic nerve crush causes upregulation of Il10 mRNA in the distal nerve portion within 
one day of axotomy, which persists up to two weeks (Gillen et al., 1998). Another study 
showed that Il10 mRNA localizes to both the proximal and distal nerve endoneurium as 
early as 14 hours after sciatic nerve transection and lasts through four weeks (Taskinen et 
al., 2000). SCs strongly upregulate Il10 mRNA within two to four days after axotomy 
(Jander et al., 1996). However, exogenous application of IL-10 to the proximal nerve 
stump does not promote neuron survival, suggesting that SC- and endoneurium-derived 
IL-10 is unlikely to be important for neuron survival via a retrograde mechanism (Xin et 
al., 2011). The ineffectiveness of exogenous IL-10 application may be attributable to its 
short half-life, estimated at 2.7 to 4.5 hours (Huhn et al., 1997). Given that production of 
IL-10 in the peripheral nerve is a temporally regulated process, a bolus of IL-10 applied 
in the periphery may not be dynamically favorable for neuroprotection. 
 There is also the question of systemic inflammation having an impact on FMN 
survival in a nonspecific manner due to the spontaneous development of enterocolitis in 
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IL-10-/- mice (Kuhn et al., 1993). However, the IL-10-/- mice utilized in this study were 
backcrossed on a C57BL/6J background, which confers resistance to the colitis 
phenotype (Berg et al., 1996; Grilli et al., 2000). No pathological weight loss was 
observed in the IL-10-/- mice used in this study. Therefore it is likely that the phenotype 
observed in this study and others (Grilli et al., 2000; Xin et al., 2011) results from the 
lack of endogenous IL-10 in the CNS rather than nonspecific gut inflammation. 
 Given the results of this study and reports in the literature, a new hypothesis has 
been formulated for the neuroprotective role of IL-0 in the FMNuc. The first part of this 
hypothesis emphasizes constitutive production of IL-10 in the FMN and inducible 
production of IL-10 from astrocytes as being dually important for FMN survival after 
axotomy. Future experiments will focus on dual elimination of IL-10 production by both 
neurons and astrocytes for observation of effects on FMN survival. This could be 
achieved by employing CRISPR/Cas9-mediated deletion of IL-10 from one cellular 
source imposed on a Cre/Lox background for deletion of IL-10 from the other. 
Additionally, while it has been shown that IL-10 from a peripheral immune source in the 
context of antigen presentation and T cell differentiation is not sufficient for FMN 
survival, the question of whether it is necessary for neuroprotection has not been 
answered. Central expression of IL-10 may not be capable of mediating neuroprotection 
if a lack of IL-10 in the periphery (such as from an APC) leads to failure of 
neuroprotective T cell development. IL-10-/- bone marrow transplantation into irradiated 
WT donors would restrict IL-10 expression to the central compartment while eliminating 
it from APCs and other immune effectors in the peripheral compartment.  
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The second part of the new hypothesis proposes two main neuroprotective 
mechanisms of IL-10 action: 1) direct trophic influences on the neuron and 2) 
immunomodulatory effects on infiltrating adaptive immune effectors and resident glia. 
To evaluate direct trophic influences on the neuron, Cre recombination of the floxed 
Il10ra locus could be targeted to the Thy1 promoter for inducible knockdown (as was 
performed for IL-10 in this study) or to the motoneuron differentiation gene Hb9 for 
constitutive knockdown (Arber et al., 1999). This would evaluate whether IL-10 receptor 
signaling in neurons is necessary for their neuroprotection. The role of IL-10 signal 
transduction in infiltrating T cells is explored in Aim 2 of this study and will be further 
discussed in section 5.2. 
 
5.2. Aim 2 Discussion 
 Both CD4+ T cells and IL-10 are necessary for FMN survival after axotomy 
(Serpe et al., 2003; Xin et al., 2011). Although regulatory T cells make IL-10 and are 
neuroprotective in many injury and disease models (Groux et al., 1997; Mayo et al., 
2016; Taylor et al., 2006; Xie et al., 2015; Zhao et al., 2012; Zhou et al., 2017), CD4+ T 
cells depleted of the CD25+ regulatory subset are sufficient to rescue FMN survival when 
transferred into immunodeficient mice (DeBoy et al., 2006a). In fact, IL-10 derived from 
a CD4+ T cell source is not required for neuroprotection in this injury model at all, as  
IL-10-/- CD4+ T cells are as efficacious as WT CD4+ T cells at rescuing FMN survival 
when adoptively transferred into RAG-2-/- mice (Xin et al., 2011). Additionally, total IL-
10 protein levels do not significantly change in the FMNuc after axotomy; rather, it is 
likely that a cellular and spatial shift in IL-10 production (Aim 1 of this study) as well as 
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an increase in IL-10R signaling is the main driving force for IL-10-mediated 
neuroprotection after FNA (Xin et al., 2011). While immunodeficiency causes transient 
depression of IL-10 levels in the FMNuc during the early post-injury phase (Xin et al., 
2011), the effect is modest and occurs prior to the significant T cell infiltration observed 
by others (Raivich et al., 1998; Villacampa et al., 2015). Therefore it remains unclear as 
whether these two neuroprotective pathways, IL-10-mediated and adaptive immune-
mediated, are linked or act independently of one another. Aim 2 of this study sought to 
determine whether such a link exists by characterizing adaptive immune cell 
participation in neuroprotective IL-10 receptor signaling after facial nerve axotomy. 
For the first part of this aim, it was hypothesized that the adaptive arm of the 
immune system, being critical for neuroprotection, is also necessary for normal levels of 
IL-10R expression in the FMNuc. If true, this would bridge a gap between CD4+ T cell-
mediated neuroprotection and the central neuroprotective IL-10 cascade. Prior to testing 
this hypothesis, it was necessary to determine whether T cells must communicate with 
cells in the FMNuc remotely (i.e., across the blood-brain barrier) or are capable of 
traveling into the FMNuc parenchyma and interacting directly with resident cells there. 
This would indicate whether central expression of IL-10R and other markers are 
potentially effected by direct T cell contact. The second part of Aim 2 investigated IL-
10R expression by infiltrating T cells themselves. In the discussion for Aim 1, it was 
hypothesized that the induction of IL-10 expression by astrocytes could inhibit or 
otherwise modulate the infiltrating adaptive immune response to axotomy. For Aim 2, it 
was hypothesized that IL-10R expression by infiltrating T cells (and therefore their 
susceptibility to IL-10 signaling in the FMNuc) was necessary for immune-mediated 
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neuroprotection, potentially by influencing their activation against self-antigen and 
subsequent modulation of the glial milieu after axotomy. 
 
5.2.1. CD4+ T cells are capable of extravasation into the FMNuc parenchyma after 
axotomy where they may interact with central cells directly to mediate neuroprotection 
 After their initial activation in the periphery, T cells must interact with MHCII on 
a central APC, mostly likely microglia, to confer neuroprotection after axotomy (Byram 
et al., 2004). In order to interact with central microglia, CD4+ T cells must be capable of 
homing to the FMNuc after axotomy, extravasating across the blood-brain barrier to enter 
the CNS parenchyma, and migrating toward regions of high microglial activation. 
Previous work using single-label IHC has reported the presence of CD3+, CD4+, and 
CD8+ cells in the FMNuc after axotomy (Bohatschek et al., 2004; Ha et al., 2007a; 
Huang et al., 2012; Raivich et al., 1998; Villacampa et al., 2015). However, given the 
limitations of single-cell IHC as well as the potential expression of CD4 on non-T cells, 
including microglia and macrophages (Almolda et al., 2009), it was necessary to perform 
co-IHC of CD3 with CD4 to demonstrate that true CD4+ T cells infiltrate the FMNuc 
after FNA. Furthermore, the ability of CD4+ T cells to leave the blood vessels and enter 
the FMNuc parenchyma has not been demonstrated definitively. In the aforementioned 
studies, lack of co-IHC to label the penetrating blood vessels of the FMNuc left the 
question of whether the T cells remain restricted to the vascular compartment 
unanswered. The 14 dpo time point was selected for analysis as this represents the peak 
of T cell infiltration in the literature (Bohatschek et al., 2004; Raivich et al., 1998). 
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 The results in this study indicate that true CD3+CD4+ T cells are found within the 
FMNuc after axotomy. The remaining CD3+CD4- cells are likely CD8+ T cells. 
Importantly, it appears that CD4+ T cells are not restricted to the lumen of blood vessels 
in the FMNuc. In fact, some CD4+ T cells are observed lying in close proximity to or 
extending pseudopod-like structures toward Nissl-stained FMN cell bodies. Therefore 
CD4+ cells are capable of both homing to the FMNuc after axotomy and extravasating 
across the blood-brain barrier to interact with central cells. CD4+ T cell localization near 
FMN cell bodies is likely mediated at least in part by the Th2-associated chemotactic 
cytokine CCL11, which is induced in astrocytes after axotomy (Wainwright et al., 
2009c). T cells must express CCR3, one of the receptors for CCL11, in order to confer 
neuroprotection (Wainwright et al., 2009b).  
Having translocated into the FMNuc parenchyma, CD4+ T cells must next 
interact with a central source of MHCII in order to confer neuroprotection (Byram et al., 
2004). Microglia are the most likely candidates for central APC due to their established 
roles as central innate immune players expressing MHCII and T cell co-stimulatory 
molecules, which are weakly expressed or absent in activated astrocytes (Aloisi et al., 
2000b; Cross & Ku, 2000; Hayes et al., 1987; Kreutzberg, 1996; Satoh et al., 1995). One 
study in the axotomized FMNuc showed that only perivascular macrophages, but not 
microglia, express MHCII (Liu et al., 2005); however, this observation is contradicted by 
numerous other studies demonstrating FMNuc MHCII expression in both perivascular 
macrophages and microglia, but not astrocytes or FMN (Hurley & Coleman, 2003; Petitto 
et al., 2003; Raivich, 2002; Streit et al., 1989a; Villacampa et al., 2015). Our laboratory 
has also shown that MHCII expressed on microglia, not perivascular macrophages, is 
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necessary for CD4+ T cell-mediated neuroprotection (Byram et al., 2004). In the current 
study, CD4+ T cells appear to associate with microglial nodules, which is in agreement 
with other studies showing accumulation of CD3+ T cells near microglial clusters after 
FNA (Raivich et al., 1998; Villacampa et al., 2015). Microglial nodules in the FMNuc are 
associated with phagocytosis of dead neurons and are characterized by strong MHCII 
immunoreactivity, making them potential “hotspots” for presentation of neuronal antigen 
to infiltrating T cells (Huang et al., 2012; Villacampa et al., 2015).  
 
5.2.2. CD4+ T cells are necessary for normal upregulation of IL-10 receptor expression 
after axotomy, regardless of their own IL-10 receptor expression or signaling capability 
The ability of the peripheral immune system to regulate central gene expression in 
the FMNuc is well established (Setter et al., 2018b). CD4+ T cells likely regulate gene 
expression via direct interactions with resident central cells, as it has now been 
demonstrated that they are capable of translocation across the blood-brain barrier into the 
FMNuc. Because CD4+ T cells are critical for IL-10-mediated neuroprotection despite 
not being the obligate IL-10 source (Xin et al., 2011), it was hypothesized that T cells 
potentiate IL-10R gene expression and thus may promote downstream IL-10 signaling in 
the FMNuc. To determine whether the adaptive arm of the immune system affects central 
expression of the IL-10R, analysis of both IL-10R subunit genes, Il10ra and Il10rb, was 
performed after FNA. IL-10RA is the ligand-binding subunit expressed preferentially on 
immune cells and is often referred to as the inducible subunit, whereas IL-10RB is 
expressed on a broader population of immune and non-immune cells and often has 
constitutive expression (Moore et al., 2001). Although IL-10RB is considered a 
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promiscuous receptor subunit that is shared with other IL-10 family cytokines, it is 
necessary for IL-10 signal transduction, and loss of IL-10RB recapitulates the pathology 
observed in IL-10-/- animals (Kotenko et al., 1997; Spencer et al., 1998; Zdanov, 2010). 
Axotomy induced upregulation of both receptor subunit genes, although induction of 
Il10ra was greater than that of Il10rb. Induction of both subunits was significantly 
decreased under immunodeficient conditions. This effect was specific to the CD4+ T cell, 
as adoptive transfer of isolated CD4+ T cells restored IL-10R subunit expression. These 
data indicate that there are two components of IL-10R induction after axotomy: an 
intrinsic response of the FMNuc to injury that triggers partial induction of IL-10R 
expression, and a CD4+ T cell-dependent component required for full induction. 
The change in IL-10R expression that is dependent on CD4+ T cells could be 
accounted for by 1) induction of IL-10R expression on central cells, such as neurons, that 
is triggered by the presence of CD4+ T cells, 2) infiltration of IL-10R-expressing T cells 
into the FMNuc, or 3) a combination of both mechanisms. To answer this question, 
CD4+ T cells deficient in IL-10RB were transferred into immunodeficient mice. Despite 
lacking functional IL-10R, these CD4+ T cells were nonetheless able to restore IL-10R 
subunit expression in the FMNuc. Il10rb-/- CD4+ T cells actually produced a greater 
increase in Il10ra expression after axotomy than did WT CD4+ T cells. This may have 
been a compensatory increase in response to a failure of IL-10R signaling in transgenic T 
cells. It is unknown whether transcription of Il10ra is dependent upon Il10rb; therefore, 
expression of Il10ra by infiltrating Il10rb-/- CD4+ T cells could theoretically account for 
the entirety of the change observed in Il10ra expression, although this is unlikely. The 
change in Il10rb triggered by the presence of Il10rb-/- T cells, however, can only be 
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explained by an induction on central cells. Therefore, it appears that CD4+ T cells 
regulate expression of IL-10R (at least the RB subunit) by inducing its expression on 
central cells in the FMNuc. However, the presence of IL-10R on infiltrating T cells 
cannot be ruled out by this study. Expression of IL-10R on naïve T cells is low, but is 
induced upon T cell activation (Akdis & Blaser, 2001; Joss et al., 2000). It has been 
observed in our laboratory that expression of other T cell receptors (such as CD3, CD4, 
and CD8) is rarely detectable by qPCR amplification in the FMNuc after axotomy 
(unpublished observations), despite the presence of these cells being confirmed by IHC. 
The failure of qPCR to detect T cell markers is likely due to the relatively low numbers 
of T cells that actually infiltrate the FMNuc compared to the populations of resident 
neurons and glia; the relatively low expression of receptors on T cell surfaces 
(nonetheless important for T cell function [Kamanaka et al., 2011]); and/or a lack of 
active transcription of receptor subunits in T cells due to their stable expression on the 
cell membrane. In conclusion, CD4+ T cells are necessary for full induction of IL-10R 
expression in the FMNuc, and they perform this function at least in part by triggering 
gene expression in central cells. 
 A previous study from our laboratory showed no difference in IL-10R expression 
between WT and RAG-2-/- mice; however, only the seven dpo time point was 
investigated (Xin et al., 2011). It makes sense that analysis of later time points would be 
necessary to detect differences in central receptor expression that are mediated by the 
peripheral immune system, because at seven days the majority of CD4+ T cells are still 
located within the draining cervical lymph nodes and have not yet mobilized to the 
FMNuc (Xin et al., 2008). One study has shown that IL-10R immunoreactivity (receptor 
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subunit not specified) localizes to neurons in the FMNuc constitutively and actually 
decreases at 7 dpo, with at least partial restoration of expression occurring by 14 dpo 
(Villacampa et al., 2015). The same study did not detect IL-10R expression on astrocytes 
after axotomy, which conflicts with results from our laboratory (Xin et al., 2011); 
however, both report IL-10R expression on neurons. Combined with the gene expression 
data in this study, the transient decrease in IL-10R immunoreactivity described by 
Villacampa et al. (2015) suggests that axotomy causes an early loss of IL-10R protein 
displayed on the FMN cell membrane that is accompanied by a compensatory increase in 
IL-10R mRNA production for restoration of IL-10R signaling at later time points. The 
immune system may therefore have an instrumental role in promoting recovery of IL-10R 
expression on injured FMNs, as CD4+ T cells are necessary for full induction of IL-10R 
gene expression in the FMNuc after axotomy. 
 A recent study on immune-mediated neuroprotection in the context of 
chemotherapy-induced peripheral neuropathy (CIPN) bears striking similarities with our 
observations after FNA. In this study, both CD8+ T cells and IL-10 are necessary for 
recovery of normal sensation after CIPN; however, the T cell is not the requisite source 
of IL-10. Rather, the presence of CD8+ T cells is necessary for upregulation of Il10ra 
mRNA in dorsal root ganglion neurons after paclitaxel-induced injury (Krukowski et al., 
2016). This study as well as ours support a role for T cell regulation of the IL-10 
signaling cascade via induction of IL-10R expression on neurons after peripheral nerve 
injury. 
 IL-10 has direct trophic actions on neurons. Both primary cortical and spinal cord 
neurons express IL-10R in vitro (Chen et al., 2016; Zhou et al., 2009b). Application of 
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exogenous IL-10 to primary cortical neurons undergoing oxygen-glucose deprivation 
downregulates expression of pro-apoptotic Bax while increasing expression of Bcl-2, 
promoting neurite outgrowth, and enhancing synaptogenesis in a JAK1/STAT3/Netrin-1-
dependent fashion (Chen et al., 2016). Treating primary spinal cord neurons with IL-10 
activates a number of pathways in these neurons, including the JAK1/STAT3, PI3K-
AKT, and GSK-3β pathways. Interestingly, activation of AKT in these neurons causes 
NF-κB activation (rather than inhibition downstream of the JAK1/STAT3 pathway, the 
typical mechanism in immune cells) which promotes expression of Bcl-2 and Bcl-xL and 
prevents release of cytochrome c. By these mechanisms, IL-10 prevents glutamate-
induced excitotoxicity in cultured neurons (Zhou et al., 2009b). Exogenous IL-10 
treatment also improves neuron survival in vivo after spinal cord injury through 
regulation of the same pro- and anti-apoptotic factors (Zhou et al., 2009a). 
 It is possible that the IHC labeling described in previous studies of the FMNuc 
(Villacampa et al., 2015; Xin et al., 2011) failed to capture the expression of IL-10R on 
other relevant cell types after axotomy. Both astrocytes and microglia can express IL-
10R, and IL-10 has dramatic effects on glial inflammation in the context of injury and 
disease. Therefore, the consequences of IL-10 signaling through glia is worthy of 
discussion. IL-10R is present on both primary astrocytes and microglia in vitro, but is 
preferentially expressed by astrocytes when the two are co-cultured (Ledeboer et al., 
2002; Norden et al., 2014). Astrocytes that have been stimulated with IL-10 produce 
TGFβ in vitro, which suppresses pro-inflammatory cytokine section by microglia and 
increases microglial expression of CX3CR1 and the IL-4 receptor (Norden et al., 2014; 
Norden et al., 2016). IL-10-stimulated astrocytes also downregulate expression of genes 
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associated with macrophage activation and chemotaxis (Mayo et al., 2016). These studies 
support a role for IL-10R signaling in astrocytes as a mechanism of indirect microglial 
regulation. However, the opposite has also been demonstrated: one study showed that IL-
10 suppresses astrocyte proliferation and hypertrophy after corticectomy, but does not 
have this effect on isolated astrocytes in vitro. Therefore, the observed effects were 
hypothesized to be downstream of a suppressive influence of IL-10 on microglia 
(Balasingam & Yong, 1996).  
In microglia, IL-10 suppresses genes associated with pro-inflammatory 
macrophage activation, such as Il1b, Il6, Nos2, and Cd40 (Mayo et al., 2016), as well as 
the production of IL-12, TNFα, NO, and other reactive oxygen species (Lodge & Sriram, 
1996; Qian et al., 2006). Similar to its effects on macrophages in the periphery, IL-10 
decreases MHCII expression by microglia and inhibits their ability to activate CD4+ T 
cells (Mizuno et al., 1994; Williams et al., 1996). In combination with IL-4 and TGF-β, 
IL-10 promotes the conversion of microglia toward a neuroprotective M2 phenotype 
(Kiyota et al., 2012; Zhang et al., 2014; Zhou et al., 2017). 
In conclusion, CD4+ T cells are necessary for full induction of IL-10R expression 
in the FMNuc after axotomy. IL-10 signaling in neurons is known to have direct trophic 
and anti-apoptotic effects, whereas IL-10 signaling through glia suppresses glial 
inflammation and antigen presentation. Studies that have attempted to localize IL-10R 
expression in the FMNuc after axotomy are concordant in their identification of neurons 
as constitutive expressers of IL-10R (Villacampa et al., 2015; Xin et al., 2011). CD4+ T 
cells may therefore have an important role in maintaining this expression to promote 
neuron survival after injury. 
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5.2.3. CD4+ T cells must express functional IL-10 receptor in order to confer 
neuroprotection 
 Il10rb-/- CD4+ T cells regulate overall IL-10R gene expression in the FMNuc 
similarly to WT CD4+ T cells, which rescue FMN survival after axotomy (Serpe et al., 
2003). Therefore, it was surprising that Il10rb-/- CD4+ T cells were incapable of rescuing 
FMN survival in RAG-2-/- mice to WT levels. This was not due to a failure of Il10rb-/- T 
cell survival until 28 dpo, as viable T cells were detectable in splenic follicles in the 
immunodeficient host. A failure of Il10rb-/- T cells to home to the FMNuc is also 
unlikely, due to their aforementioned ability to regulate central gene expression. 
Therefore the loss of the ability of these CD4+ T cells to confer neuroprotection is 
presumably specific to the loss of IL-10R signaling within the T cell itself.  
IL-10 can act on T cells via direct and indirect mechanisms. Indirectly, IL-10 acts 
on APCs to suppress Th1-associated cytokine secretion in the context of antigen 
presentation and T cell activation (Fiorentino et al., 1989; Fiorentino et al., 1991b). There 
is also evidence that IL-10 can cause APCs to skew T cell differentiation toward the Th2 
phenotype (Liu et al., 1998). Loss of this indirect pathway can lead to pathogenic Th1 
responses (Berg et al., 1996). Directly, IL-10 signaling in T cells inhibits CD28 
phosphorylation (Akdis et al., 2000; Joss et al., 2000; Schandene et al., 1994; Taylor et 
al., 2006). CD4+ T cells must receive at least two forms of stimulation by an APC in 
order to become activated against antigen: their T cell receptors and CD4 co-receptor 
must engage with antigen presented on MHCII on the APC, and the T cell co-stimulatory 
molecule CD28 must also engage with APC CD80/86 (B7.1/7.2). Loss of either of these 
cues causes T cell anergy, or the loss of immune response against antigen (Janeway & 
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Bottomly, 1994). Therefore, IL-10 acts directly on the T cell to inhibit the CD28-
dependent co-stimulatory pathway and induce T cell tolerance. This loss of tolerance to 
self-antigen after axotomy in Il10rb-/- CD4+ T cells could be the cause for their failure to 
mediate neuroprotection, despite the fact that their presence still triggers expression of 
IL-10R in central cells in the FMNuc. 
The harmful role of autoreactive T cells is supported by studies finding that 
immunization with or without neural antigen exacerbates motoneuron loss after spinal 
cord injury and FNA, indicating an overall detrimental effect of enhancing adaptive 
immune reactivity on neuron survival. The immunization strategies employed by these 
studies likely optimized a Th1 response to injury (Ankeny & Popovich, 2007; Jones et 
al., 2004). These findings initially appear to contradict a previous study from our 
laboratory, which concluded that T cells must be activated both peripherally and centrally 
in order to confer neuroprotection after axotomy (Byram et al., 2004). However, this 
study investigated the importance of MHCII expression on microglia in the central 
compartment after axotomy, and not the need for central T cell re-activation per se. 
Therefore, the need for CD4+ T cells to encounter MHCII centrally in order to confer 
neuroprotection could actually represent the necessity of MHCII-induced anergy in the 
absence of CD28 co-stimulation, rather than T cell re-activation. Alternatively, the 
neuroprotective capacity of Th2 cells may benefit from central re-activation by microglia, 
whereas IL-10 may be necessary to suppress Th1 or Th17 responses that are not 
neuroprotective.  
 Other studies have demonstrated the importance of IL-10R signaling specifically 
in T cells. Adoptive transfer of CD4+ T cells overexpressing a dominant-negative form of 
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IL-10RA into immunodeficient mice causes the development of spontaneous enterocolitis 
(Kamanaka et al., 2011). In mouse models and in humans, T cells nonresponsive to IL-10 
escape Treg control, proliferate to a greater degree, and produce higher amounts of 
inflammatory cytokines including Th17 and IFNγ, both of which activate macrophages 
and promote cellular autoimmunity (Kamanaka et al., 2011; Shouval et al., 2017). 
Interestingly, IL-10R signaling and downstream STAT3 phosphorylation are also 
defective in CD4+ T cells from patients with systemic lupus erythematosus and MS, 
suggesting that a failure of T cell suppression by IL-10 may play an important role in 
autoimmune disease, including in the CNS (Cui et al., 2011; Martinez-Forero et al., 
2008). 
 
5.2.4. CD4+ T cells lacking IL-10R induce greater expression of genes associated with 
microglial activation, antigen presentation, T cell co-stimulation, and synaptic pruning 
after axotomy 
 Anergic T cells are not merely inactive cells without immunological functions. 
They can suppress the proliferation of other effector T cells and prevent cell-mediated 
toxicity against skin grafts in vivo (Chai et al., 1999). Anergic T cells also actively 
suppress APCs in vitro by downregulating their expression of MHCII, CD80, and CD86, 
thereby preventing antigen presentation and co-stimulation for other T cells (Vendetti et 
al., 2000). Both of these actions are antigen-specific and mediated by cell-cell contact. 
Conversely, effector T cells induce greater expression of MHCII and co-stimulatory 
molecules on macrophages/monocytes largely via IFNγ signaling (Schroder et al., 2004). 
Therefore it was hypothesized that loss of IL-10R signaling in CD4+ T cells would lead 
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to increased activation of central macrophages (i.e. microglia). The 14 dpo time point was 
analyzed according to the rationale described in previous experiments; additionally, this 
time point represents the peak of microglial gene expression in the FMNuc after axotomy 
(Setter et al., 2018b). Genes relating to microglial activity were selected for investigation 
and divided into three categories based on associations with: 1) general activation and 
pro-inflammatory activity, 2) antigen presentation and T cell co-stimulation, and 3) 
complement deposition and synaptic pruning. 
 
5.2.4.1. Genes associated with activated microglia 
To investigate general microglial activation and pro-inflammatory cytokine 
activity, the following genes were selected: Cd68, Cd40, Tnf, Tnfrsf1, and Nos2. After 
FNA, microglia proliferate in the FMNuc (Blinzinger & Kreutzberg, 1968; Graeber et al., 
1988c; Torvik & Skjorten, 1971b). These proliferating cells lack expression of markers 
for perivascular macrophages such as ED2 and therefore are likely a true microglial 
population (Graeber et al., 1988a). mRNA for CD68, a pan-macrophage marker, 
increases in the FMNuc after axotomy (Haulcomb et al., 2014; Setter et al., 2018b) and 
corresponds with the appearance of CD68+ microglia (Wainwright et al., 2010). 
Therefore Cd68 mRNA may be used as a general marker of microglial activation (and 
potentially proliferation) in the FMNuc after axotomy. In immunodeficient mice 
reconstituted with Il10rb-/- CD4+ T cells, the level of Cd68 in the axotomized FMNuc 
was significantly greater than in animals having WT CD4+ T cells, indicating increased 
microglial activation due to the loss of T cell IL-10R expression.  
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Cd40, Tnf, Tnfrsf1, and Nos2 are genes associated with pro-inflammatory 
microglia. CD40 ligation is one of three steps critical for macrophage activation by 
effector T cells (the other two being MHCII activation and IFNγ signaling) (Banchereau 
et al., 1994). In resting microglia or in microglia that have been redirected toward an M2 
phenotype, expression of CD40 is low (Aloisi et al., 2000a; Aloisi et al., 1998; Tierney et 
al., 2009). Microglia strongly increase CD40 expression in response to LPS, IFNγ, and 
upon interacting with Th1 (but not Th2) cells (Aloisi et al., 2000a; Aloisi et al., 1998). 
Increased expression of CD40 is associated with CNS autoinflammatory disease such as 
MS and HIV-1 encephalitis (D'Aversa et al., 2008; Ponomarev et al., 2006; Tan et al., 
1999). Tnf and Nos2 (gene name for inducible nitric oxide synthase, iNOS) are also 
associated with pro-inflammatory microglial activation and are induced by LPS 
stimulation (Chhor et al., 2013; Lodge & Sriram, 1996; Park et al., 2007). Although 
TNFα and NO are essential for the innate immune response to pathogens, they exhibit 
toxic bystander effects toward neurons and glia (Lodge & Sriram, 1996; Lull & Block, 
2010; Moss & Bates, 2001; Smith et al., 2012). TNFR1 is upregulated in response to 
TNFα signaling on microglia to promote further TNF- and other pro-inflammatory 
cytokine-associated signaling in an autocrine fashion (Kuno et al., 2005). There was no 
difference in FMNuc Cd40 expression when comparing RAG-2-/- mice reconstituted with 
WT or Il10rb-/- CD4+ T cells, although Cd40 expression in the former was significantly 
elevated compared to WT. There were also no differences detected in Tnf, Tnfrsf1, and 
Nos2 gene expression. These data indicate that while Il10rb-/- T cells increase overall 
microglial activation, they do not necessarily do so in an overtly pro-inflammatory 
fashion compared to WT CD4+ T cells. It is possible, however, that alterations in 
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inflammatory markers were missed due to the time point selected for this analysis, as loss 
of Tnf expression is observed as early as 7 dpo in immunodeficient mice and is regulated 
by CD4+ T cells (Setter et al., 2018b). 
 
5.2.4.2. Genes associated with antigen presentation and T cell co-stimulation 
To investigate the hypothesis that Il10rb-/- T cells enhance antigen presentation 
and co-stimulation in the FMNuc after axotomy, the genes for MHCII (H2ab1) and co-
stimulatory molecules CD80 and CD86 were analyzed in the axotomized FMNuc.  
Il10rb-/- T cells induced significantly higher H2ab1 and Cd86 expression after axotomy 
compared to WT or immunodeficient mice given WT CD4+ T cells. This increase in gene 
expression is likely specific to microglia, as microglia have been demonstrated to express 
MHCII in the FMNuc (Hurley & Coleman, 2003; Petitto et al., 2003; Raivich, 2002; 
Streit et al., 1989a; Villacampa et al., 2015). MHCII and CD86 are both expressed at low 
levels in resting microglia, but increase upon LPS and IFNγ stimulation, TLR activation, 
or when interacting with Th1/17 cells (Aloisi et al., 2000a; Aloisi et al., 1998; Lodge & 
Sriram, 1996; Menendez Iglesias et al., 1997; Olson & Miller, 2004; Satoh et al., 1995). 
Astrocytes rarely express MHCII or co-stimulatory molecules (De Simone et al., 1995; 
Kreutzberg, 1996; Satoh et al., 1995), even in the course of massive peripheral immune 
infiltration such as during EAE (Cross & Ku, 2000; Hoftberger et al., 2004). 
Th1 cells induce upregulation of MHCII on microglia, but Th2 cells suppress its 
expression on microglia via an IL-4-dependent mechanism, implicating MHCII as an 
important mediator of Th1/Th2 cross-regulation (Aloisi et al., 2000a; Suzumura et al., 
1994). Therefore, the increase in H2ab1 expression caused by Il10rb-/- CD4+ T cells in 
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this study may be a consequence of Th1 subset skewing and loss of the neuroprotective 
Th2 subtype. Low CD86 is associated with tolerogenic APC and M2 anti-inflammatory 
microglia (Ma et al., 2015; Steinbrink et al., 1997; Tierney et al., 2009; Zhang et al., 
2014), whereas increased MHCII and CD86 on microglia is associated with 
neurodegenerative and autoimmune conditions (De Simone et al., 1995; Hayes et al., 
1987; Ponomarev et al., 2006; Tooyama et al., 1990). Expressing MHCII on microglia at 
specific loci prior to EAE induction results in lymphocytic infiltration and lesion 
formation at the same loci (Konno et al., 1990), while blocking CD86 co-stimulation 
reduces EAE incidence and severity (Girvin et al., 2000). Overall, these data suggest that 
Il10rb-/- CD4+ T cells promote greater antigen presentation and T cell co-stimulation by 
microglia after FNA, which may facilitate harmful (or at least non-neuroprotective) 
autoimmune mechanisms effected by greater infiltration of Th1 cells. 
 
5.2.4.3. Genes associated with complement deposition and synaptic pruning 
This study showed that expression of B2m, which encodes the MHC class I 
subunit β2-microglobulin, was significantly greater in RAG-2-/- mice reconstituted with 
WT CD4+ T cells compared to WT or non-reconstituted RAG-2-/-. However, expression 
of B2m in RAG-2-/- mice given Il10rb-/- CD4+ T cells was the greatest of all conditions 
investigated. MHCI is an antigen presenting molecule important for cell-mediated 
immunity and neuronal plasticity during development (Shatz, 2009). Unlike MHCII, 
which is predominantly expressed on professional APCs, MHCI has the potential to be 
expressed on all nucleated cells in the body.  
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There is some evidence that FMN cell bodies express MHCI protein after 
axotomy (Maehlen et al., 1988), although this is contradicted by other studies in the 
FMNuc (Bohatschek et al., 2004; Streit et al., 1989b). However, multiple studies have 
indicated that MHCI mRNA also co-localizes with motoneurons (Lidman et al., 1999; 
Linda et al., 1998). This discrepancy indicates that motoneuron MHCI is likely translated 
or transported away from the cell body and expressed on distal processes. MHCI at 
synapses appears to promote axon regeneration by regulating the stripping of upper 
motoneuron synaptic inputs from the dendrites and cell bodies of axotomized lower 
motoneurons, although studies conflict as to whether MHCI has this effect by promoting 
(Sabha et al., 2008) or restricting (Berg et al., 2013; Oliveira et al., 2004) the extent of 
synaptic stripping. However, conclusions drawn from studies showing impaired axon 
regeneration in MHCI-deficient rodents (Akdagli et al., 2016; Oliveira et al., 2004) must 
be tempered by the fact that genetic MHCI deficiency will also result in loss of CD8+ T 
cells, complicating the phenotype. It is also worth noting that activated microglia can 
induce expression of MHCI on neuron cell bodies, resulting in cytotoxic T cell attack and 
subsequent neurodegeneration (Cebrian et al., 2014); however, this does not explain the 
failure of Il10rb-/- CD4+ T cells to mediate neuroprotection, as the reconstituted RAG-2-/- 
mice in this study lack CD8+ T cells.  
Microglial upregulation of B2m is another explanation for the changes observed 
in this study. Multiple studies indicate that microglial expression of MHCI accounts for 
much of its total upregulation in the FMNuc after axotomy (Bohatschek et al., 2004; 
Lidman et al., 1999; Streit et al., 1989b). In the FMNuc, MHCI immunoreactivity is 
highly specific to microglia and appears to be important for their ability to form 
 
122 
phagocytic nodules and interact with infiltrating CD8+ T cells (Bohatschek et al., 2004; 
Streit et al., 1989b). Microglia are capable of presenting exogenous antigen on MHCI to 
CD8+ T cells (Beauvillain et al., 2008; Jarry et al., 2013). Furthermore, MHCI expression 
by microglia may be necessary for recruitment of CD8+ T cells to the central 
compartment (Malo et al., 2018). As with MHCII, IFNγ produced by CD4+ T cells can 
induce expression of MHCI on macrophages (King & Jones, 1983; Wong et al., 1983). It 
is likely that infiltrating CD4+ T cells instruct microglia to upregulate MHCI and thereby 
prime microglia for CD8+ T cell interactions. The observed increase in B2m expression 
in immunodeficient mice given WT CD4+ T cells in this study may therefore simply 
indicate a greater degree of microglial activation. This potentially becomes 
hyperactivation in immunodeficient mice given Il10rb-/- CD4+ T cells, as has been 
suggested by changes in other markers such as Cd68, H2ab1, and Cd86. 
Similarly to B2m, expression of complement protein C3 was also increased in 
RAG-2-/- given WT CD4+ T cells relative to WT or RAG-2-/-, and RAG-2-/- given   
Il10rb-/- CD4+ T cells had the greatest C3 expression compared across all conditions. 
Peripherally, complement is integral to the innate immune response by facilitating 
opsonization of pathogens and promoting macrophage chemotaxis and phagocytosis 
(Lubbers et al., 2017). Complement can also promote T cell activation, differentiation, 
and proliferation (Strainic et al., 2008). After axotomy, complement in the periphery is 
beneficial for efficient removal of myelin and proper Wallerian degeneration (Ramaglia 
et al., 2009; Ramaglia et al., 2007; Ramaglia et al., 2008). Centrally, complement has a 
role in tagging synapses for microglial-mediated synaptic pruning (Schafer et al., 2012). 
Activated microglia in the FMNuc express high levels of complement receptor after 
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axotomy (Berg et al., 2013; Graeber et al., 1988a). In the axotomized FMNuc, the 
complement components C1, C1q, C3, and C3d co-localize with microglia located in 
close proximity to neuronal membranes, but not with neurons or astrocytes. C3 mRNA 
expression is most concentrated in microglia. mRNAs for clusterin and CD59, both of 
which are complement cascade inhibitors, co-localize with FMN cell bodies (Mattsson et 
al., 1998). Therefore it is likely that the increase in C3 expression in this study is due to 
production by activated microglia.  
In neurodegenerative disease, microglia can become inappropriately activated to 
phagocytize synapses labeled with C3 (Hong et al., 2016). High levels of complement 
components, including C3, and exaggerated pruning are associated with synapse loss in 
neurodegenerative and psychiatric diseases. These include Alzheimer’s disease, ALS, and 
schizophrenia (Chiu et al., 2009; Forsyth & Lewis, 2017; Heurich et al., 2011; Hong et 
al., 2016; Kawamata et al., 1992; Shen et al., 1997; Sta et al., 2011). Complement can 
also promote the release of superoxide anions by microglia (Colton & Gilbert, 1987). 
Blocking the complement cascade improves neuron survival after traumatic brain injury 
by suppressing the microglial/macrophage response to injury (Fluiter et al., 2014). 
Because synapse elimination can be either protective (by shielding injured FMN from 
excitotoxic inputs) or destructive (as occurs in neurodegenerative disease), the moderate 
increase in C3 caused by adoptive transfer of WT CD4+ T cells in this study likely 
represents a “Goldilocks zone” for optimum synaptic stripping after axotomy, whereas 




To summarize, both B2m and C3 expression were elevated in RAG-2-/- mice 
given CD4+ T cells, but Il10rb-/- CD4+ T cells elicited greater increases in mRNA 
expression than WT CD4+ T cells. If the observed changes in B2m expression are taken 
to represent neuronal rather than microglial induction, then this has interesting 
implications for synaptic stripping. MHCI and complement are believed to have opposing 
roles, respectively inhibiting and promoting synapse loss (Berg et al., 2013). Induction of 
both after axotomy suggests that the increase in MHCI is a compensatory response by the 
injured FMN to resist synaptic loss effected by activated microglia and complement. It is 
interesting that expression of B2m and C3 are increased in RAG-2-/- reconstituted with 
WT CD4+ T cells, which confer neuroprotection after axotomy, as well as in those given 
Il10rb-/- CD4+ T cells, which fail to support FMN survival. However, expression of both 
markers was increased to a greater degree after transfer of Il10rb-/- CD4+ T cells, 
indicating that there is a threshold of “safe” innate immune activation that is exceeded 
when Il10rb-/- CD4+ T cells are present. 
 
5.2.5. Summary of results 
 These data show that CD4+ T cells are capable of crossing the blood-brain barrier 
and entering the FMNuc parenchyma after axotomy, where they may interact directly 
with central cells, including microglia. It is likely through this direct cell-cell contact that 
they modulate gene expression in the FMNuc. Because overall levels of IL-10 in the 
FMNuc do not change in response to axotomy (Xin et al., 2011), induction of 
neuroprotective IL-10 signaling depends on increased IL-10R expression. The presence 
of CD4+ T cells triggers upregulation of IL-10R gene expression on central cells in the 
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FMNuc after axotomy, indicating that CD4+ T cells are necessary for full induction of 
neuroprotective IL-10 signaling. Despite regulating IL-10R gene expression on other 
cells normally, T cells that are unresponsive to IL-10 themselves fail to confer 
neuroprotection after axotomy. This may be due to a loss of IL-10-mediated T cell 
tolerance to self-antigen. T cells lacking IL-10RB increase gene expression associated 
with greater microglial activation (Cd68), antigen presentation (H2ab1 and B2m), T cell 
co-stimulation (Cd86), and synapse elimination (C3 and B2m) in the FMNuc after 
axotomy. This suggests that one neuroprotective mechanism of IL-10 in the FMNuc is to 
prevent neurotoxic autoimmunity by inducing T cell tolerance to self-antigen.  
Although the percentages of FMN survival are approximately the same between 
non-reconstituted RAG-2-/- and RAG-2-/- given Il10rb-/- CD4+ T cells, the gene signatures 
in the FMNuc differ dramatically. For example, immunodeficient mice exhibit a blunted 
glial response to axotomy (Setter et al., 2018b), whereas the microglial reaction in   
RAG-2-/- given Il10rb-/- CD4+ T cells appears to be hyper-responsive. The amount of 
FMN death that occurs after FNA is likely also due to differing mechanisms. In non-
reconstituted immunodeficient mice, the increase in FMN death is due to loss of Th2 
cells, which may normally promote neuroprotection in part by triggering the upregulation 
of IL-10R in the FMNuc. In immunodeficient mice given Il10rb-/- CD4+ T cells, the 
neuroprotective effect of CD4+ T cells triggering central IL-10R expression is still 
present, but the benefit may be nullified by the actions of a neurotoxic autoreactive T cell 
that is unresponsive to IL-10. In the spectrum of immune responses that can occur after 
axotomy, either extreme is not favorable, and optimum FMN survival likely depends on 
balanced activation of immune effectors. 
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5.2.6. Limitations of this study and future directions 
 In this study and others, in vivo demonstrations of microglia presenting antigen to 
CD4+ T cells have relied on indirect measures. For example, MHCII co-localizes with 
phagocytic microglial nodules in the literature (Huang et al., 2012; Villacampa et al., 
2015), and this study has shown that CD4+ T cells also accumulate in association with 
IBA1+ microglial nodules; therefore, the conclusion is drawn indirectly that microglia 
interact with CD4+ T cells via MHCII-T cell receptor interactions. Triple 
immunohistochemistry for CD4, IBA1, and MHCII in the axotomized FMNuc in 
combination with confocal microscopy would definitively demonstrate CD4+ T cell-
microglia interactions in the context of antigen presentation. Similar analysis should also 
be performed with astrocytes to determine their antigen presentation capacity. Baseline 
antigen presentation events should then be compared to conditions of immunodeficiency 
and the presence of defective T cells lacking IL-10R expression. Utilization of IHC or 
Western blot to confirm that the observed mRNA changes coincide with alterations in 
protein levels should also be performed. IHC or FISH would also be useful to localize 
markers that the literature indicate may be expressed in different cell types, such as B2m 
as described in section 5.2.4.3. 
 In the literature, loss of IL-10R signaling in T cells causes predominant Th17 
responses (Kamanaka et al., 2011; Shouval et al., 2017). In this study, increased 
expression of genes associated with microglial activation in the FMNuc suggests that loss 
of IL-10RB may cause CD4+ T cell differentiation to become skewed toward a non-
neuroprotective subtype rather than the Th2 subtype, which confers neuroprotection 
(Deboy et al., 2006b). The increase in MHCII gene expression in the presence of Il10rb-/- 
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T cells after FNA supports this, as MHCII is induced by Th1 cells and suppressed by Th2 
cells (Aloisi et al., 2000a; Suzumura et al., 1993). To determine whether loss of IL-10RB 
affects T cell subset differentiation, adoptive transfer of WT and Il10rb-/- CD4+ T cells 
could be performed one week prior to axotomy, followed by collection of draining 
cervical lymph nodes at one week post axotomy for flow cytometric analysis. 
Additionally, although equal numbers of T cells were transferred into immunodeficient 
mice, loss of IL-10RB on T cells may influence how many T cells actually infiltrate the 
FMNuc after axotomy. Quantification of T cell numbers in the FMNuc would be 
informative. 
 Finally, the exact mechanisms behind the failure of Il10rb-/- T cells to mediate 
FMN survival are unknown. Although increased microglial activation has been 
implicated, Il10rb-/- CD4+ T cells do not cause increased expression of canonical pro-
inflammatory genes such as Nos2 or Tnf in microglia. However, microglia can induce 
neuronal death by other mechanisms, such as excitotoxic glutamate release (Brown & 
Vilalta, 2015). The increase in complement component C3 expression triggered by 
Il10rb-/- CD4+ T cells in this study also suggests that increased synaptic elimination (or 
even C3-mediated phagocytosis of stressed neurons) may play a role in neuronal survival 
after axotomy. Further exploration of these mechanisms will be necessary to fully 




5.4. Significance of findings 
5.4.1. Feasibility of IL-10 as a therapeutic 
In agreement with the literature, the results from this study demonstrate 
neuroprotective roles of IL-10 in the injured nervous system. The application of IL-10 as 
a therapeutic drug is made difficult by the fact that it has a short half-life of only a few 
hours (Huhn et al., 1997). Studies utilizing systemic IL-10 for the treatment of peripheral 
autoimmune diseases have attempted to circumvent this with more frequent 
administration, but this results in undesirable side effects (Saxena et al., 2015). 
Furthermore, IL-10 does not cross the blood-brain barrier, complicating its application 
for the treatment of CNS injury and disease (Kastin et al., 2003). Many studies showing 
CNS benefits of IL-10 have administered the cytokine via intraspinal or 
intracerebroventricular injection, which is highly invasive (Bluthe et al., 1999; Brewer et 
al., 1999).  
Even if a significant amount of IL-10 administered systemically cannot reach the 
injury site, it may still be capable of attenuating inflammation if the CNS pathology is 
mediated by infiltrating peripheral cells. However, the timing of systemic IL-10 
administration is important. After contusive spinal cord injury, systemic administration of 
IL-10 is capable of suppressing TNFα production by activated monocytes and reducing 
lesion volume if administered acutely (30 minutes after injury) (Bethea et al., 1999). To 
surmount these difficulties, many studies have utilized viral vectors or other transgenic 
means of increasing and maintaining IL-10 expression centrally (Ayers et al., 2015; Cua 
et al., 2001; Joniec-Maciejak et al., 2014; Kiyota et al., 2012; Koeberle et al., 2004; Zhou 
et al., 2009a), but these methods entail significant ethical issues for use in human 
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patients. Finally, enhancing IL-10 levels is unlikely to be effective for conditions in 
which the IL-10R is hypo-responsive, as has been observed in some MS patients 
(Martinez-Forero et al., 2008). 
By elucidating the effects of IL-10 on the ability of CD4+ T cells to mediate 
neuroprotection, conclusions from this study support a rationale for using cell-based 
immunomodulatory therapies in peripheral nerve injury. T cells that are autoreactive to 
self-antigen released by axotomy may be harmful for neuron survival, but complete 
elimination of T cells altogether is also detrimental. Tolerizing T cells to self-antigen ex 
vivo in the presence of exogenously applied IL-10, or alternatively by exposing T cells to 
self-antigen in the context of CD28 blockade, followed by re-infusion into patients may 
confer enhanced neuroprotective benefits. Similar therapeutic approaches have been 
explored for the treatment of graft versus host disease and demonstrate great promise 
(Blazar et al., 1998; Chen et al., 2003; Dillinger et al., 2017; Zeller et al., 1999).  
 
5.4.2. A new theory of IL-10-mediated neuroprotection after axotomy 
 Collectively, the conclusions from this body of work support dual roles for IL-10-
mediated neuroprotection that involve: 1) trophic support for injured FMN and 2) 
suppression of neurotoxic immune activation. An illustration summarizing this new 
theory of IL-10-mediated neuroprotection is shown in Picture 2. Constitutive neuronal 
expression of IL-10 could likely serve a homeostatic role for maintenance of synapses 
and resistance to stress via JAK1/STAT3 signaling (Chen et al., 2016), while also 
suppressing apoptosis in response to injury (Chen et al., 2016; Zhou et al., 2009a, 2009b). 
Injury-induced IL-10 production by astrocytes presumably also contributes to trophic 
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influences on injured FMN, and may additionally restrict harmful immune infiltration, as 
is observed in MS (Cannella & Raine, 1995; Hulshof et al., 2002; Voskuhl et al., 2009). 
The redundancy of both neuronal and astrocytic production of IL-10 after FNA means 
that neither source is strictly necessary for FMN survival, as compensation can occur 
when production by one of these sources is lost.  
In order for IL-10 to perform these functions, its receptor must also be expressed 
on the necessary target cells. For a direct trophic role of IL-10 to be efficacious, this 
means IL-10R must be expressed on neurons, which is supported by the literature (Fouda 
et al., 2013; Villacampa et al., 2015; Xin et al., 2011). An indirect trophic role could be 
mediated via IL-10R expression on other FMNuc resident cells, potentially including 
astrocytes (Xin et al., 2011). CD4+ T cells are required for normal induction of IL-10R 
expression in the FMNuc after axotomy, bridging the gap between IL-10-mediated and 
immune-mediated neuroprotection. Importantly, for IL-10 to mediate suppression of 
potentially harmful immune responses to axotomy, its receptor must also be expressed on 
infiltrating immune effectors. The failure of IL-10R-deficient CD4+ T cells to confer 
neuroprotection after FNA supports this hypothesis. Normal IL-10 signaling in T cells 
results in their tolerance to antigen (Akdis & Blaser, 2001; Akdis et al., 2000; Joss et al., 
2000; Taylor et al., 2006); this tolerance can be passed along to other T cells and APCs in 
a cell contact-dependent and antigen-specific fashion (Chai et al., 1999; Vendetti et al., 
2000). Loss of tolerance to self-antigen through loss of IL-10 signaling could potentially 
result in dis-inhibition of a harmful autoimmune response to nerve injury, given that T 
cells unresponsive to IL-10 promote a microglial gene signature indicative of enhanced 
antigen presentation, T cell co-stimulation, and synaptic elimination. These discoveries 
 
131 
contribute to the growing body of knowledge characterizing the mechanisms of immune-




Picture 2: Summary illustration for proposed mechanism of IL-10-mediated 
neuroprotection. 
 
A) IL-10 function in animal with WT CD4+ T cells. 1) FMN make IL-10 constitutively, 
astrocytic production of IL-10 is inducible, and microglial production of IL-10 is 
unknown. 2) The appearance of CD4+ T cells triggers greater induction of central IL-10R 
expression, possibly potentiating the effects of IL-10 after FNA. 3) The IL-10R must also 
be expressed on T cells to induce their tolerance to self-antigen. 4) Tolerized T cells 
promote benign microglial reactivity. B) When T cells do not express the IL-10R, they 
promote a microglial gene signature indicative of autoimmunity, which may contribute to 
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